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CHAPTER 1 
Introduction. 
GENERAL INTRODUCTION 
Interferons are glycoproteins of cellular origin produced by 
eukaryotic cells in response to viral infections or other 
stimuli. They affect a wide variety of cellular and viral 
processes with species specificity in these actions. Interferons 
were discovered in 1957 by A. Isaacs and J. Lindemann during a 
study of viral interference: influenza infected embryo cells 
released a substance which, when added to other cells in culture, 
made these cells resistant to viral infections1. Next to the 
antiviral properties the interferons showed to have profound 
effects on the cell growth and differentiation. Furthermore, they 
affect the immune system in various ways, eg. stimulation of 
nonspecific cellular defense mechanisms as well as modulation of 
the specific immunological reactions. In the first 20 years, 
progress has been slow, mainly for the reason that purification, 
molecular characterization and production have met great 
difficulties. Initially the working mechanism of interferons were 
studied using the material obtained from human cells. A 
considerable amount of this research started in blood transfusion 
centres with the use of interferons produced by buffy coat cells 
after these had been infected with Sendai virus, a mild 
parainfluenza virus2. This material, designated leukocyte-
interferon, was used for a number of clinical trials. Nowadays 
large amounts of interferon have become available after the 
introduction of DNA-recombinant techniques, which have allowed 
the production of interferons with high quality and purity. 
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CYTOKINES, LYMPHOKINES, INTERLEUKINS AND INTERFERONS 
"Lymphokines" such as B-cell growth factor, tumor necrosis 
factor, T-cell growth factor and macrophage activating factor are 
polypeptides produced by lymphocytes in the regulation of the 
immune system. They have local effects, modulating intracellular 
immune responses, as well as systemic effects. When it became 
clear that their effects are not restricted to lymphoid cells the 
more general name of "cytokines" was introduced. Since most 
lymphokines have diverse biologic properties not reflected in 
their names, it was decided to rename these as an "interleukin" 
followed by a number, except the interferons, tumor necrosis 
factor and colony stimulating factors. Thus, B-cell growth factor 
was renamed "interleukin-4", T-cell growth factor "interleukin-
2". Especially the establishment of the genetic code of different 
cytokines made clear that one cytokine could have various names 
defining its different intracellular activities, e.g. macrophage 
activating factor appeared to be genetically the same as 
interieron-tf, and cachectin the same as tumor necrosis factor-α, 
lymphotoxin the same as tumor necrosis factor -β. Some 
immunological interactions, especially of the interferons, are 
graphically summerized in figure I3·* · s . A more detailed 
explanation is given on page 14 . 
DEFINITION OF INTERFERONS 
Interferons are defined by their antiviral effect 
specific and different from antiviral effects of 
which is 
synthetic 
tumor cell 
Figure 1. Possible ways of immunomodulatory activities and direct 
antitumor effects of interferons and other cytokines. (TNF=tumor 
necrosis factor, IFN=interferon, IL=interleukine,NK-cell=natural 
killer cell)(Adapted from D Goldstein,J Laszlo: The role of 
interferon in cancer therapy: a current perspective. CA-A Cancer 
Journal for Clinicians 1988; 38: 258-90). 
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compounds. Pretreatment of cells by interferon causes protection 
against subsequent virus infection, due to the ability of the 
interferons to inhibit intracellular replication of a spectrum of 
viruses of both RNA and DNA types, by interfering the RNA and 
protein synthesis*. 
CLASSIFICATION OF INTERFERONS 
The interferons were initially categorized according to their 
cell of origin, inductive stimuli or physical-chemical properties 
such as acid lability. Nowadays the interferons are divided into 
3 main classes: α, ß, tf, according to their antigenic types. 
INTERFERON-a 
Originally interferon-α was produced by viral stimulation of 
leukocytes ("leukocyte interferon") or lymphoblastic cells 
("lymphoblastoid interferon"), resulting in a variety of a-
interferons of 80% homology7. Until now over 20 subtypes have 
been recognized. The coding gene for interferon-α is localized on 
chromosome 9e. Interferon-az is now available as DNA-recombinant 
interferon. Presently three subtypes of recombinant interferon-a 
are commercially available: recombinant interferon-azA, 
interferon-azв and interferon-azс, differing one another in only 
one or two amino-acids. 
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INTERFERON-ß 
Human fibroblast cells in culture stimulated by viruses or semi-
synthetic double-strained RNA were another source of interferon, 
explaining "fibroblast interferon" as the former name of 
interferon-ß9. Two interferon-ß genes are localized on chromosome 
9, just as interferon-α, and it shows 30% homology with 
interferon-α on the genetic level8. 
INTERFERON-^ 
A third interferon, formerly called "immune-interferon", was 
identified as produced by T-lymphocytes, cells of the immune 
system, when treated with a mitogen or an appropriate antigen. 
Because of the exclusive production by lymphocytes interferon-?} 
is also a lymphokine. The only gene, coding for interferon-tf, 
shows 10% homology with the genes for interferon-α and -β, and is 
located on a different chromosome: chromosome 12 1 0. 
INTERFERON-RECEPTORS 
The interferon-α and -β (Type I interferons) bind to a common 
receptor, whereas interferon-tf (Type II interferon) binds to a 
different receptor. The genes for the interferon-α, -β and -tf-
receptors are localized on chromosome 211 1 . This may explain the 
greater sensitivity for interferons in patients with Down 
syndrome1'-1э. Rapid internalization has been shown, followed by 
degradation and secretion. It is not known whether 
internalization of interferon is required for it to be active. A 
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down-regulation of receptors on the cells is present, resulting 
in vitro in degrading sensitivity after treatment with 
interferons. 
CELLULAR EFFECTS 
Two pathways are triggered, both leading to inhibition of protein 
synthesis. One induces formation of 2'5'-oligo A- synthetase 
which polymerizes ATP to 2'S'-oligoadenylate, which is an 
extremely powerful inhibitor of protein synthesis. The other 
system, also involving ATP, leads to the phosphorylation of an 
essential co-factor of protein synthesis by forming a new protein 
kinase14. The three interferons induce a common set of 
polypeptides. Interferon-^ induces in addition an extra set of 
polypeptides, indicating the unique biological function13. Other 
cellular changes occur in the cytoskeleton and cell membrane14. 
Increment of the expression of tumor-associated antigens, HLA 
class I antigens (all interferons16), HLA class II antigens (only 
interferon-tf17) and ßz-microglobulin are other interferon related 
effects18. 
ANTIPROLIFERATIVE EFFECTS 
Interferons may have a negative effect on the multiplication of 
cells by slowing the cell cycle, without accumulation in any 
particular phase of the cell cycle1'. Antiproliferative effects 
have been observed in in-vitro cultures of stem cells of normal 
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bone marrow20-23 and of bone marrow cells of patients with 
chronic myelogenous leukemia24·25 or acute leukemia26·27. 
IMMUNOMODULATIVE ACTIVITIES (see Figure 1) 
Next to the already mentioned increased expression of cell 
surface antigens the interferons, especially interferon-^, modify 
the functions of Natural Killer-cells (NK-cells), T-lymphocytes, 
B-lymphocytes and monocytes/macrophages. The interferons, 
especially interferon-α, enhance NK-activity by recruiting NK-
precursors and by amplifying the lytic rate and recycling 
capacity of target-binding cells2β. Repeated administration of 
interferon to patients is associated with a gradual return of NK 
cell activity to pretreatment levels14. 
The human mixed lymphocyte reaction is augmented by interferons 
due to an increment of the reactivity of cytotoxic T-cells14 . On 
the other hand generation of suppressor T-cells is inhibited by 
interferon29. The maturation of B-cells is positively influenced 
by interferons, especially interferon-tf30. Interferon influences 
antibody formation in vitro: low doses enhance and high doses 
suppress Ig synthesis28. Antibody responses have not been found 
to be influenced by interferon in vivo31. Cytotoxic and 
phagocytic functions of monocytes are enhanced by interferon28. 
Interferon-tf appeares to be a major macrophage activating 
factor32. 
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ANTITUMOR ACTIVITIES 
The interferons do have anti-tumor activities on the basis of a 
direct anti-proliferative effect, a change in the phenotype of 
the tumor cells and the increased expression of oncogenes, by 
modulating the differentiating capacity of cells and by their 
ability to activate the immune response33. 
CLINICAL APPLICATIONS IN HEMATOLOGICAL DISEASES 
HAIRY CELL LEUKEMIA (HCL) 
HCL is a lymphoproliferative disease characterized by a 
proliferation of lymphocytic cells in bone marrow and spleen, and 
less frequently in lymph nodes and liver34. The proliferating 
cells show a hairy aspect of the cytoplasm when examined in the 
microscope. In most patients a pancytopenia and monocytopenia is 
present with increased risk of infections and hemorrhagic 
accidents33'36. Before the introduction of interferon-α (IFN-a) 
patients were treated by splenectomy, resulting in various 
remission-periods with in most cases relapse of pancytopenia37-
3 9
. In case of relapse, patients were treated with cytostatic 
drugs or corticosteriods, resulting in prolonged hypoplasia and 
few sustained responses40-42. In the phase I dose-finding studies 
of IFN-a, promising responses were encountered in patients 
suffering from HCL 4 3· 4 4 confirmed by many reports4»-4β. Even in 
patients who attain "complete remissions" relapses are 
frequently encountered after discontinuation of IFN-a. The 
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mechanism of action of IFN-a is unknown. In vivo, positive and 
negative changes in NK-activity have been observed without proven 
importance for response4'-»3. Hairy-cells can produce B-cell 
growth factor (interleukin-4)'* · 33 . In-vitro and in-vivo 
observations have given evidence of IFN-a interfering the 
production of B-cell growth factor and interrupting an autocrine 
loop of hairy cells, inducing growth of hairy cells by production 
of B-cell growth factor'S,S6. 
CHRONIC MYELOGENOUS LEUKEMIA (CML) 
CML is a myeloproliferative disease characterized by leukocytosis 
with immature myeloid cells in the circulating blood, 
splenomegaly, hypercellular bone marrow, and presence of Ph'-
chromosome positive metaphases in nearly all patients"-59. The 
Ph'-chromosome is a reciprocal translocation between the long 
arms of chromosome 9 and 22 t(9:22)(q34:qll) resulting in a 
transcript, inducing abnormal tyrosine kinase, which may be 
important in the pathogenesis of CML60'*1. Leukocytosis and 
splenomegaly can be controlled by cytostatic drugs as busulfan 
and hydroxyurea. In all patients a blastic transformation is 
encountered 1-10 years (median 3 years) from diagnosis, which can 
be treated with intensive chemotherapy resulting in a survival of 
only several months62. Potential cure is possible in a subgroup 
of patients when treated with allogeneic bone marrow 
transplantation. This procedure is limited to patients below 50 
years of age with an HLA-identical donor 6 3· β 4. Recently, 
encouraging results are reported of the treatment of CML with 
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IFN-σ and -tf resulting in possible reduction in percentage Ph'-
chromosome positive metaphases (cytogenetic conversion) бз-ті_ 
Even a disappearance on molecular level of the Ph'-chromosome 
positive clone has been reported72. Mechanism of action of the 
interferons in patients suffering from CML is most likely to be a 
direct suppression of the Ph'-chromosome positive myeloid 
progenitor cells2*-27·73. 
ESSENTIAL THROMBOCYTHEMIA (ET) 
Thrombocytosis may be a concomitant feature in myeloproliferative 
disorders. ET is defined as a myeloproliferative disease, 
characterized by an isolated proliferation of the megakaryocytes. 
The Polycythemia Vera Group has defined strict diagnostic 
criteria74. In mild symptom-free cases treatment with anti-
aggregant drugs may suffice, whereas thrombocyte counts of over 
1000 χ 10'/1 warrant antiproliferative treatment, as well as 
cases complicated by thrombosis or hemorrhagic accidents. 
Cytostatic drugs can control the thrombocyte count 7 3 - 7 7, but are 
also known as inducers of secondary malignancies, lungfibrosis or 
unexpectedly longterm hypoplasias7β•7'. IFN-ct seems to be a 
possible controller of thrombocytosis in myeloproliferative 
diseases as well as in ET without any known long term side 
effectse0"e3. The mechanism of action of IFN-a is probably a 
direct cytostatic effect on the megakaryocytic precursor 
cells 2 0· 2 3. 
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SIDE EFFECTS 
The side effects of IFN-a may be divided in transient and 
prolonged side effects. The transient side effects mimic a viral 
infection and consist of myalgia, fever, chills and headaches. 
These side effects occur in the first months of treatment. The 
prolonged side effects are dose-dependent and consist of fatigue, 
anorexia, nausea, hair loss, mental disturbances, itching and 
paresthesia 4 3 - 4 β··'-···ео-еэ # only in the phase I dose-finding 
studies, where high doses were used, severe neurological 
disorders were encountered84•e7. Occasionally renal diseases, 
such as nephrotic syndrome·β, interstitial nephritis89 and 
membranoproliferative glomerulo-nephritis90, have been noticed 
during IFN-a therapy. 
The side effects of interferon-^ are persistent and do not 
alleviate in time. They consist of flu-like symptoms such as 
fever, chills, myalgia, headache and others such as nausea, loss 
of energy, mental disturbances. They are partially controlled by 
paracetamol, but still interfere daily life activities. A dose 
dependency is not clearly present70·71·. 
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CHAPTER 2 
Results of a multi-center trial on the efficacy of 
recombinant-a2с-interferon in hairy cell leukemia. 
M.J.B.P. Werter, M.J.J.T. Bogman, J.Th.Ρ.Janssen, 
В.E. de Pauw, C.A.H.Haanen 
Translation from: 
Nederlands Tijdschrift voor Geneeskunde 1987; 131: 2081-2085. 
ABSTRACT 
Twenty-nine patients with hairy cell leukemia (HCL·) and bone 
marrow insufficiency, 19 of whom had undergone splenectomy 
previously, were treated with recombinant interfегоп-агс. 
Remission induction therapy was given to the first 8 
patients for 12 weeks in dosages up to 40 χ 10*units/day, 
the other 21 patients received 5 χ IO6units/day for 12 
weeks. Maintenance treatment for all patients consisted of 5 
χ 106 units twice weekly. Twenty-four patients were 
évaluable for clinical results: 9 (38%) attained a complete 
remission and 14 (58%) entered a partial (hematological) 
remission; in 1 patient a minor response was observed after 
14 months of treatment. The early improvement of trombocyte 
and leukocyte counts were remarkable and independent of 
previous splenectomy. Severe infection was noticed in 2 
patients; one died. Severe neurological side effects were 
seen in 5 patients: in 4 during the high dose interferon-α 
induction schedule (>. 20 χ 10e units/day). Flu-like 
symptoms, anorexia and fatigue were common side effects in 
patients recieving 5 χ IO6units/day. 
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INTRODUCTION 
Hairy cell leukemia (HCL) is a lymphoproliferative disease, 
characterized by a slow proliferation of lymphocytic cells 
infiltrating the spleen and bone marrow, and to a lesser 
extent, the liver and lymph nodes1. In most patients a 
gradually developing pancytopenia is seen; in some patients 
(3-4%) leukemia is observed. Monocytopenia and high 
infection rates are striking2·э. Diagnosis is based on 
histology of bone marrow and spleen and may be confirmed by 
tartrate resistent acid phophatase staining on lymphocytes 
of peripheral blood, bone marrow or imprints of histological 
material4. In immunophenotyping mostly a monoclonal 
proliferation of B-cells is seen9, in few cases a 
proliferation of T-cells is observed*. 
Before the introduction of o-interferon splenectomy was the 
treatment of choice. Hematological remission, with a high 
relapse rate, was achieved in 70-90% of the patients7-10. 
The results of chemotherapy after splenectomy were poor and 
often associated with longterm aplasia, life-threatening 
infections, and rarely with longstanding improvement10"'э. 
The results of Quesada et al. with α-interferon warranted a 
further investigation of this treatment modality14. 
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MATERIAL AND METHODS 
Patients were enrolled in this study when the diagnosis HCL 
was confirmed histologically in combination with progressive 
disease resulting in bone marrow insufficiency and/or 
recurrent infections. Progressive disease was considered to 
be present if hemoglobin (Hb) fell <_ 7,3 mmol/1, 
granulocytes were <. 0,5 χ 10» or thrombocytes were <_ 70 χ 
10·/1. 
Histological material such as spleen tissue, lymph nodes and 
bone marrow biopsies were revised by one of us (MJB), as 
well as the consecutive bone marrow biopsies in order to 
estimate the reduction of hairy cell proliferation while on 
treatment with recombinant interferon-агс (rIFN-агс). 
Twenty-nine patients (26 male, 3 female) were enrolled. The 
diagnosis hairy cell leukemia was established 1 to 84 months 
before treatment with rIFN-агс (median 8 months). Initially, 
the diagnosis lymphoproliferative disease or non-Hodgkin 
lymphoma was established in 2 patients. Revision was done 
after 3 and 25 years, respectively (median 15 months). Three 
patients had been pretreated. In 7 patients (27%) 
pancytopenia was observed. Anemia (Hb <_ 7,3 mmol/1) was 
present in 24 patients (83%), 8 of whom (33%) transfusion 
dependent. Thrombopenia (<. 70 χ 109/1) was present in 14 
patients (48%), 1 of whom was transfusion dependent. Twelve 
patients (41%) were granulopenic (<. 0,5 χ 109/1). 
28 
The first 8 patients were treated for 12 weeks according to 
a phase I study with escalating doses rlFN-o^c up to 40 χ 
10· units/day and the next 21 patients with 5 χ IO6 
units/day for 12 weeks. Maintenance treatment consisted of 5 
χ 10« units twice weekly. rIFN-aac was administered 
subcutaneously or intramuscularly. 
Definitions of response were: 
Complete remission (CR): <. 5% hairy cells in the bone 
marrow, Hb >. 7,3 mmol/1, granulocytes >. 1,5 χ 10»/1, 
thrombocytes >. 100 χ 109/1, no hairy cells in peripheral 
blood, no splenomegaly. 
Partial remission = hematological remission (HR): 
reduction in hairy cells in the bone marrow of more than 
50%, Hb >. 7,3 mmol/1, granulocytes >. 1,5 χ 10* IX, 
thrombocytes >. 100 χ 10»/1, no splenomegaly. 
- Minimal response (MR): reduction of hairy cells in the 
bone marrow of >. 25% and one of the next criteria: Hb >. 7,3 
mmol/1, granulocytes >. 1,5 χ 10'/1, thrombocytes >. 100 χ 
10»/1. 
RESULTS 
Between October 1984 and January 1987 29 patients treated 
with rIFN-агс were évaluable for assessment of side effects. 
Twenty-four of them (21 male, 3 female) were évaluable for 
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Table 1. Clinical data of 24 patients suffering from hairy cell leukemia 
treated with α-interferon. 
pat M/F1 age diagnosis2spleen3 Hb granulo trombo IFN results 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
M 
И 
M 
F 
M 
M 
и 
F 
M 
M 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
M 
M 
M 
years 
54 
54 
62 
42 
47 
47 
53 
53 
38 
45 
69 
39 
79 
69 
56 
78 
55 
34 
61 
68 
42 
73 
52 
54 
months 
14 
60 
5 
43 
17 
1 
6 
3 
14 
8 
6 
5 
84 
12 
7 
32 
4 
15 
1 
1 
45 
2 
1 
48 
+/-
_ 
-
-
-
-
+ 
-
-
-
+ 
-
-
-
-
+ 
-
-
-
+ 
+ 
-
+ 
+ 
-
mmol/1 
7,6#« 
9,4 
6,0t 
5,7 
6,9 
4,5 
6,4# 
7,1 
6,3 
5,9 
6,0 
8,7 
7,3 
4,8# 
6,1 
8,3 
5,0 
7,6# 
8,31 
6,7# 
5,4 
6,7 
5,4# 
7,7 
х10в/1 
0,01 
2,2 
0,7 
0,3 
0,2 
0,6 
0,6 
0,7 
1,2 
0,2 
1,6 
0,2 
2,3 
0,1 
0,7 
0,5 
0,2 
1,1 
0,6 
1,6 
1,1 
0,6 
0,1 
0,5 
xlOVl 
16 
274 
54 
69 
27# 
19 
283 
142 
77 
48 
144 
425 
75 
10 
63 
50 
90 
70 
49 
80 
212 
99 
18 
227 
months 
29* 
26* 
29* 
9 
14 
16 
26* 
5 
23* 
22* 
20» 
20+ 
19* 
6 
18+ 
13* 
12» 
11* 
10* 
8* 
7» 
5' 
5* 
Э 
CR/HR/MR 
CR(3)» 
CR(18) 
HR(3)-PD(12) 
HR (7) 
MRU) 
CR (8) 
CR(2) 
HR(6) 
CR(12) 
HR(7) 
HR(6)-PD(12) 
CR(18) 
HR(7) 
HR(6) 
CR(6) 
HR(3) 
HR(3) 
HR (6) 
HR(5) 
CR(5) 
HR(7) 
HR(5) 
CR(3) 
HR(2) 
1) M: maie, F: female 2) Period from diagnosis to therapy with a-
interferon in months 3) -: splenectomy, +: spleen in situ 4)#: 
transfusion-dependent 5) CR: complete remission, HR: hematological 
remission, MR: minor respons, PD: progressive disease while on treatment. 
In brackets the months of treatment until the result mentioned. 
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response. The clinical data are summarized in Table 1. The 
other 5 patients were not évaluable for response for various 
reasons: treatment duration of less than 3 months (4x), no 
histological confirmation of the diagnosis HCL (lx). Four of 
the remaining 24 patients were lost from follow-up. In one 
this was due to lack of compliance after 14 months of 
treatment (resulting in MR with progressive disease in the 
following months); in 3 patients this was due to side 
effects (lx congestive feelings after 5 months resulting in 
HR lasting up to 14* months; 2x psycho-depressive syndrome 
after б and 9 months respectivily, resulting in HR with 
progressive disease after 2 and 14 months with a second 
response to reinstitution of rIFN-azc). 
Thrombocytes 
The first sign of response was an increase of thrombocyte 
counts, in most patients during the first month of treatment 
(Fig. 1). Only in patients with an initial thrombocyte count 
of <. 100 χ 10*/1 a transient decline was seen during the 
first weeks of treatment. In 1 patient suffering from M. 
Rendu-Osier a hemorrhagic diathesis was seen, resulting in 
fatal cerebral bleeding. 
Granulocytes 
Granulopenia <. 1,0 mmol/1 was present in 21 patients (88%). 
Ten patients had a granulocyte count of <. 0,5 χ 10*/1 with 
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8 9 10 Π 12 
months 
Figure 1. Recovery of hemoglobin, granulocytes, thrombocytes 
and monocytes during 12 months treatment with rlFN-aac 
expressed as percentage of 24 patients with normalized 
values. percentage of patients with Hb >. 7,3 mmol/1, 
percentage of patients with granulocyte counts >, 1,5 
χ 109/1, —percentage of patients with thrombocyte 
counts > 100 χ 109/1, percentage of patients with 
monocyte counts >. 0,2 χ 109/1. 
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consequently an increased infection rate. After 2 months of 
treatment the granulocyte count was >. 1,5 χ 10e/1 in 12 out 
of 24 patients (50%). Only in 1 patient persistent 
granulopenia even after 14 months of treatment was observed 
(see Fig. 1). The transient increase of granulopenia in all 
patients during the first weeks of treatment was remarkable. 
Monocytes 
Only 1 patient had a normal monocyte count before treatment 
with rIFN-02c. In 17 out of 24 patients (70%) a recovery of 
monocytes was observed (>. 0,2 χ 109/1). In 7 patients 
monocytopenia persisted despite 3,5,10,12,14,20,22 months of 
treatment (see Fig. 1). 
Hemoglobin 
The recovery of hemoglobin (Hb) was rather slow: after 4 
months of treatment, only 12 patients (50%) achieved Hb-
levels of >_ 7,3 mmol/1. After 8 months of treatment all 
patients had a normal Hb (see Fig. 1). 
Bone marrow 
The reduction of hairy cells in the first months of 
treatment in 19 patients who underwent consecutive bone 
marrow biopsies was striking (see Fig. 2). 
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months 
Figure 2. Reduction in percentage of hairy cells in 
consecutive bone marrow biopsies of 19 patients. The median 
is marked. 
Spleen 
Ten out of 29 patients had no splenectomy before treatment 
with rIFN-02c. One died during the first month of treatment 
due to a splenic rupture; another patient, suffering M. 
Rendu-Osler, died of a cerebral hemorrhage. From the 8 
remaining patients 3 had no palpable spleen before 
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treatment; the spleen was resp. 2,4,4,7,17 cm palpable below 
the costal margin in 5 patients. Within 2 months the spleen 
size normalized in all patients. 
Clinical results in 24 patients 
At the end of the study 9 patients (38%) had achieved a 
complete remission, and 14 patients (58%) a hematological 
remission. In 1 patient a minor response was seen despite 14 
months of treatment. After an initial response two patients 
showed progressive disease accompanied by an increase of 
hairy cells in the bone marrow while on maintenance therapy 
(see Fig. 2). The high complete remission rate in patients 
without splenectomy (50%) compared to the other patients 
(31%) was noteworthy. 
One patient out of 29 died after 2 weeks of treatment due to 
a Gram-positive septicemia and generalized mycosis. 
Urosepsis was encountered in 1 patient with normal 
granulocyte and monocyte counts. Several non-life-
threatening infections were observed. 
Side effects 
The side effects are summarized in Table 2. Nearly all 
patients had flu-like symptoms like chills, fever and 
myalgia 4 to б hours after injection. These symptoms 
disappeared after the first week of treatment. 
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Table 2. Side effects in 26 men and 3 women suffering from 
hairy cell leukemia treated with α-interferon. 
Side effects number of patients (%) 
fever, chills 
myalgia 
fatigue 
anorexia, nausea 
headache 
hair loss 
neurological disorders 
- during phase I-study 
- during phase II-study 
paresthesia 
dry mouth, dry eyes 
impotentie 
itching 
apathy, depression 
Occasionally complaints of dizziness, eczema, photophobia, 
arthralgia, congestive feelings, diarrhoea and gynaecomasty 
were encountered. 
* of 8 patients 
21 (72) 
18 (62) 
18 (62) 
13 (45) 
7 (24) 
5 (17) 
5 (17) 
5 (17) 
4 (14) 
4 (15) 
4 (14) 
3 (10) 
4 
1 
- During the phase I study neurological complications, such 
as pareses, parkinsonism and coma were present in 4 out of 8 
patients18. These complications appeared to be reversible 
and dose-dependent. One out of 21 patients treated with the 
lower induction dosis of 5 χ 10' units/day a neurological 
syndrome was observed characterized by loss of coordination. 
Interestingly, a deficiency of vitamin Bi was established in 
2 out of 5 patients with neurological complaints. In 3 of 
them a recovery was seen after administration by vitamin B-
complex. 
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- In 5 patients elevation of the transaminases was seen. No 
dose adaptation was required. 
- Renal toxicity was not observed. 
The treatment was tolerable for most patients. In 8 patients 
a dose-reduction was necessary due to side effects. In 7 
patients treated with rlFN-aac >. 5 χ IO6 units/day adaptions 
were made. In 3 patients treatment was discontinued 
because of side effects. 
DISCUSSION 
The short time relapse to clinical response is remarkable. 
High response rates have been reported by others 1 7 - 2 0. As 
all patients had normal Hb, granulocyte and thrombocyte 
count within 6 months of treatment, it was impossible to 
distinguish complete from hematological remissions without a 
bone marrow biopsy. It was clear from our data that no 
complete remission was observed as long as monocytopenia 
persisted. It is unclear how long maintenance therapy 
should be continued. After termination of o-interferon a 
relapse is to be expected17. It has been observed by us and 
others that retreatment with α-interferon is feasible. 
In 5 patients treatment was discontinued because of side 
effects. In 3 of them a psycho-depressive disease already 
had been diagnosed in the past. Therefore in patients with a 
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psychiatrie history caution in treatment with α-interferon 
is necessary. 
A possible disadvantage of α-interferon is that it should ne 
given by injection. Nearly all patients were able to inject 
themselves subcutaneously. If necessary, help was given by 
the family physician or a nurse. 
The place of splenectomy in relation to α-interferon 
treatment is not clear. Treatment with α-interferon is 
instituted with increasing frequency before splenectomy is 
performed21·22. In another study, a significant difference 
in thrombocyte counts was noticed between patients with and 
without previous splenectomy17. We could not confirm this 
observation in our study. On the contrary, patients without 
splenectomy showed higher complete remission rates. 
Recent publications suggest a similar response rate in HCL 
with lower doses α-interferon which are accompanied by less 
side effects23> 2* . The mode of action of α-interferon in HCL 
is not clear. A possible effect of an increased number of 
"natural killer"-cells is suggested23, although in-vitro 
studies have shown differentiating and antiproliferative 
activities of a-interferon2'·27. 
CONCLUSION 
α-Interferon is an efficacious therapy in HCL, without any 
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curative potential. A dosis of 5 χ 10* units rIFN-azc daily 
is safe. It is not clear whether treatment with α-interferon 
is preferable to splenectomy. In view of the potency of a-
interferon in the treatment of HCL, this modality should be 
considered strongly in patients with an increased risk 
during surgery. 
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CHAPTER 3 
Comparison of clinical efficacy and toxicity of conventional and 
optimum biological response modifying doses of interferon 
alpha-2C in the treatment of hairy cell leukemia: 
a retrospective analysis of 39 patients. 
Günther Gastl, Marjon Werter, Ben de Pauw, Christoph Neri, Walter 
AulitzJcy, Irene von Lüttichau, Herbert Tilg, Josef Thaler, Alois 
Lang, Klaus Abbrederis, Paolo Coser, Heinz Huber, Roswitha 
Flener, Christoph Huber 
Leukemia 1989; 3: 453-460. 
ADDENDUM 
Eleven out of 18 patients in group A are also part of the 
patients described in Chapter 2. 
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Response Modifying Doses of Interferon Alpha-2C in the Treatment of Hairy Cell 
Leukemia: A Retrospective Analysis of 39 Patients 
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Hairy cell leukemia (HCL) has been shown to be extraordinarily 
sensitive to treatment with alpha-mterferon (IFN) In order to 
define clinically effective IFN doses associated with minimal 
toxicity, the therapeutic efficacy and side effects of recombinant 
IFN-alpha-2C treatment of HCL were compared for two different 
dose regimens 1 β patients (group A) received conventional doses 
of recombinant IFN alpha-2C (2 χ 10'U m2) for a median time of 
35 weeks (range 26-52 weeks) and 21 patients (group B) re­
ceived optimum biological response-modifying doses of IFN-
alpha-2C (0 2-0 6 χ 106U m2) for a median time of 31 weeks (range 
12-52 weeks) Interferon was administered daily subcutane-
ously for 3 months and then every second or third day Induction 
of neopterln excretion was chosen as the marker tor definition 
of biological response The smallest IFN dose causing maximum 
In vivo Induction of biosynthesis of the GTP-degradahon prod­
uct neopterln was deemed 'biologically optimal Both dose 
regimens were effective, but the low-dose regimen was almost 
tree of toxicity Thus, m HCL patients alpha-IFN related toxicity 
can be separated from its antineoplastic activity Low doses of 
alpha-IFN should be considered for treatment of HCL patients 
who develop toxic side effects and for primary treatment of HCL 
patients with severe cytopenia 
INTRODUCTION 
HAIRY CELL leukemia (HCL) a monoclonal В cell dis order first deitribed by Bouronilc et al (I) is charac 
len/edby pancytopenia and bone marrow mliltratmn »ith hairy 
cells (Н(_ч) which may be accompanied by neutropenia 
splenomegaly and trequcnt opportunistic infections (2) Until 
recently splenectomy was considered the treatment of choice 
that leads to recovery ol peripheral blood counts in more than 
half of the patients (3 4) In 1984 Qucsadaetal I irst reported 
encouraging therapeutic results ot natural alpha-lhN m patients 
with advanced HCL (5) Subsequently these results were con 
firmed bv numerous groups using various dose regimens and 
diflercnt sources of natural or recombinant alpha IFN (6-12) 
In these trials IFN doses ranging trom 2 - l 2 x 10',U were ap 
plied (for review see reis Π I4) Irrespective ol the IFN 
dosage the vast majority of patients showed marked improve 
ment of blood parameters within 2-4 months ol treatment 
(13 14) Although alpha IFN provides ettcctive palliation lor 
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HCL it seemingly docs not eradicate the malignant HC clone 
since complete responses arc rare and almost never include 
complete normalization of the bone marrow (15 16) Addi 
tionally in the majority ol patients cessation of ІГ\ therapy 
is followed by gradual disease recurrence and some torm of 
maintenance therapy is thus required in most cases (16-19) 
Although the therapeutic efficacy of IFN alpha tor treatment 
ot HCl is well established the crucial question whether the 
therapeutic efficacy of IFN alpha can be separated from its 
toxicity is still unsolved The side effects ot IFN treatment are 
clearly dose dependent (20 21) The most trequcnt IFN related 
toxicity is a (lu like syndrome with fever fatigue myalgia 
and/or anorexia (20 21) In addition most HCL patients treaicd 
with conventional IFN alpha doses developed transient myc 
losuppression during the first month of therapy (6 22) Мус 
lotoxicity can be particularly serious in patients with severe 
neutropenia and or thrombocytopenia Common adverse ef 
fects after prolonged IFN treatment also include malaise and 
weight loss Thus studies exploring the clinical efficacy of 
low and presumably less toxic IFN doses are clearly desirable 
Here we present a retrospective analysis of two different dose 
regimens of rlFN alpha 2C for treatment of HCl 18 patients 
(group A) were treated with a conventional dose ot 2 x 10'U/ 
гтГ and 21 patients (group B) with 3-10 told lower doses rang 
ing from 0 2-0 6 x lO'D/nT daily The latter represented op 
timum biological doses in the sense that those IFN doses chosen 
tor treatment were the lowest required for maximum induction 
ot the IFN dependent marker molecule neoptenn Ncoptcnn 
a pyrazino pynmidine compound is derived trom a GTP 
degradation pathway leading down to the synthesis of tctrah 
vdrobioplerin(23) In monocytes and macrophages the activity 
of the key enzyme of this metabolic pathway a GTP cyclo 
hydrolase is activated by interferons Since neoptenn is re 
leased from monocytes and macrophages which are widely 
distributed in blood and extravascular tissues this marker mol 
eculc provides a proper tool to assess cellular interferon re 
sponses in vivo (24 25) Our results indicate thai both dose 
levels arc effective in terms of disease palliation but thai the 
low dose regimen is almost free of toxicity 
MATERIAL AND METHODS 
Ptmenrs atul Trearmenl Motlalilie\ Thirl) nine palicnls wuh ad 
vaneed HCL enrolled in two clinical phase II studies were analwed 
in relrospccl The clinical and hematological data arc summarised in 
Table I Diagnosis ol HCL was based on morpholotncal and immu 
nolocical examination ot peripheral blood samples and bone marrow 
biopsies Eighteen patients (eroup A limali 1 Iemale) ssith a median 
age ot 51 vcars (ranee 14 80) rceeived a conventional dose ot rlFN 
alpha 2C (2 χ Ю'Ъ/т dailv) and 21 patients (group В 16 male S 
45 
Table 1 Characteristics of Patients with Hairy Cell Leukemia Treated with rlFN-alpha-2 
No of patients 
Age 
Sex 
Disease known lor (mo) 
Treatment belore IFN therapy 
Splenectomy 
Chemotherapy 
Steroids 
Blood indices (median f 
Hemoglobin (g dl) 
Leukocytes (χ103μΙ) 
Neutrophils (χ to 3 μ I) 
Monocytes (per μΙ) 
Platelets (x 10' μΙ) 
Spleen size (cm) 
range) 
IFN Do·» 
Conventional Dose 
(Group A) 
18 
34-80 (median 53) 
15M3F 
1-82 (median β) 
15(83°.) 
15 (83%) 
3(17%) 
7 2(4 8-12 7) 
7 2 (8 0-97 0) 
0 7(0 16-2 5) 
0 (0-160) 
80 (10-425) 
19 (14 30) 
flegimen 
Low Dose 
(Croup 8) 
21 
33-75 (median 59) 
16M5F 
0-180 (median 10) 
12 (57%) 
9 (43%) 
3 (14%) 
10 0( 4 6 13 7) 
3 4 ( 1 0-88 0) 
07 ( 0 1-2 6) 
0 ( 0-370) 
99 (24-416) 
18 (13-30) 
Sigmlicance Level 
(Avs B)* 
ns 
ns 
ns 
ρ 0 05 
pv 0 05 
π s 
ns 
ns 
ns 
ns 
η s = not signidcani 
•Mann-Whilney lest 
female) wiih a median age of 59 vcars (range 41-75) were treated 
with neoptenn guided IFN doses (0 2-0 6x ΙΟΊ! m' daily) R1FN 
alpha-2C (Boehnngcr/Ingelheim International FRG) was adminis­
tered daily by subcutaneous self administration tor 1 months and then 
every 2nd or 3rd da> 
Definition of an Optimum Biological Response moäif\in(* Dose Us 
ing the Neoptenn MarUr Because of its ease of performance and 
sensitivity to (FN the neoptenn marker was used for dclimtion ot an 
optimum biological response to exogenous IFN (21 2S) Neoptenn 
represents an intermediate product inthes>nthelicpathwd\ ot bioptenn 
(21) Monocytes and macrophages have been shown to be capable ol 
producing neoptenn when stimulated by IPNs (24) In order to deter 
mine the minimum dose of rlF-N alpha 2C inducing maximum neop 
term excretion group В patients received increasing doses ot ΙΓΝ 
starting with 0 1 χ I06U daily subcutaneously and increasing the dose 
by 0 1 x 1Û4J daily until a dose ot 2 x KPU'd was reached Serum 
neoptenn excretion was assessed daily by means of a commercialh 
available radioimmunoassay (Henning Berlin hRG) The minimum 
dose of rIFN alpha 2C needed to cause maximum neoptenn release 
was chosen for long term treatment (25) 
Substance RIFN alpha 2С(ВсгоГог*) was provided bv Bochnnger 
Ingelheim International (Ingelheim FRG) The material was highly 
purified (more than 98% purity) to a specific activus of 1 2 χ 10KL 
mg protein In contrast to our previous report (12 25) the IhN dose 
m this publication are given as international units (I U ) in (tut I '•< IO* 
1 U equal I 5 x 10*U previously reported as an internal standard ol 
the Bochnnger Ingelheim company 
Evaluation ofStud\ Patients Patients were evaluated before and I-
2 3-4 12 26 and 40-52 weeks after initiation of treatment Bone 
marrow biopsies were routinely taken before initiation of treatment 
and then at 1 month intervals In patients presenting with organo 
megaly sonography and/or С1 scans were performed every 1 months 
HCs in penpheral blood were enumerated alter Giemsa staining of 
peripheral blood smears and by indirect immunofluorescence using the 
monoclonal antibodies and Leu M5 (CRII! associated antigen mon 
ocyies/macrophages HCs) B4 (CD 19 В lymphocytes) and anti lac 
(CD 25 IL 2 receptor) As a second step reaction HTC labeled rabbit 
anti mouse Habb fragments were used Flow cytometry was per 
lormed on a f-ACS 420 (Hecton Dickinson CA) 
Bone marrow biopsies were taken from the iliac crest using Jamshidi 
needles After embedding the specimens in resin semithm sections 
(2 μΓη) wert' prepared and stained according to Giemsa (26) Total 
ccllulantv was delmed as the sum ol the relative volumes of HCs 
myeloid and other cells and the HC index (HCl) calculated using 
the formula HCl - % cellulanty x 'A HCs/IO(XK) 
In selected patients (nine from group A eight Irom group B) the 
HC infiltrate in the bone marrow was repeatc*dl\ assessed by immu 
nohistochcmistry The preparation ol bone marrow biopsies and im 
munostaming were carried out as previously described (27) Briefly 
biopsies were frozen in liquid nitrogen and cut at 5-7 τημηι m a 
cryostatc Sections were fixed in acetone and incubated with mono 
clonal antibodies Monoclonal antibodies were demonstrated by an 
indirect immunopcroxidasc technique Endogenous peroxidase ot mve 
loid cells was inhibited by glucoscoxidasc and sodium acid The fol 
lowing monoclonal antibodies were used anti HLA DR (МНС class 
II antigen) B4 ГоІ5 (С D 22 В cells) antibodies reacting with im 
munoglobuhn heavv (mu delta) or light chains (kappa lambda) Vil 
Al (CD 10 CALI antigen) anti Tac anti Leu M5 dndF-MC7(sub 
set of peripheral В cells HCs) likewise in Giemsa stained bone 
marrow biopsies the HCl was taken as a parameter ol leukemic in 
filtration 
Clinical responses were evaluated according to the classilication of 
Ratam et al (14) CR (a) was defined as normah/ation ol peripheral 
blood counts (hemoglobin ^:l2g dl platelets ^I(K) 000 μΙ and neu 
trophils ^1500 μΙ) and (b) less than 5^ HCs m bone marrow biopsv 
PR was defined as normalization of peripheral blood counts which 
however did not meet the criteria for complete remission MR was 
normalization of at least one peripheral blood count initially abnormal 
but did not meet the criteria for PR (sec Table 1) 
Staiisiu ν Hematological parameters m peripheral blood and bone 
marrow were compared between the two groups ol patients by means 
of the Mann Whitney lest The Wilcoxon signed rank test was used 
to analyze the changes in hematological parameters during IFN ther­
apy 
Table 2 Evaluation ol Bone Marrow Response ol Hairy Cell Leukemia Patients to rlFN-alpha-2C 
Hairy Cell Indei3 
IFN Dose Regimen Before IFN Therapy 
(Group A) 
After 3 6 Months 
of Therapy 
(Group B) 
Signiiicarice Level 
(A vs B)D 
Conventional dose 
(Group A η - 9) 
Low dose (Group Β η - θ) 
0 68 (0 90-0 06) 
0 З (0 6-0 06) 
0 10(0 76-0 01) 
О 25 (0 45-0 03) 
ρ 0 01 
ρ 0 05 
'Median and ranges (in parentheses) are given 
"Wilcoxon signed rank lest 
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Table 3 Response of Hairy Cell Leukemia to Convenllonal or Low-dose IFN alpha 2C Therapy' 
Response Criteria 
accofding lo Hata η el al |14)" 
CR 
PR 
MR 
No of patients 
CR Complete Remission PR - Partial Remission MR 
•For delmition see Material and Methods section 
RESULTS 
IFN dose Reg men 
Conventional Dose 
(Group A) 
2 ( 11%) 
1 ( 6%) 
15 ( 83%) 
18(100%) 
Minor Response 
^ 
Low Dose 
(Group B) 
1 ( 4%) 
10 ( 48%) 
10 ( 48%) 
21 (100%) 
Signiticance Level 
(Avs B) 
ns 
Companion of the Clinical CliaraaerntK* of the HCL Pa 
tienls Ireated w/r/i Coinenliomil or Optimum Bioloçiial Re 
ψοηκ modif\ing Dosi s of rIFN alpha 2C I his report presents 
a retrospective analysis of two phast II trials applying two 
ditterent dose schedules of rlFN-alpha-2C Fightcen patients 
(group <\) entered from 1984 to I'JHft were treated with a con 
ventional dose ot rlbN alpha 2C Since I98S 21 further pa 
tients were treated with optimum biological response moditvmg 
doses of rIFN alpha 2C which were defined as minimum doses 
triggering maximum neoptenn serum levels The patients char 
actcnstics are summan¿ed in Tabic 1 As shown the two groups 
did not differ significantly with respect to age sex or disease 
duration Disease stage of group A patients however dillercd 
from that of group В patients Fittccn patients (839Í) in group A 
presented with highly advanced HCL (stage 1 or C) but only 
eight cases (ІВЧ) with stage 1 or С were enrolled in the low 
dose trial (group B) Groups A and В also dillercd with respect 
to the type and intensity of treatment prior to rIFN alpha 2C 
therapy In group A 15 patients (8Wr) had undergone spie 
ncctomy three of whom (17%) had subsequently received ehe 
molherapy In group В nine patients had been splencetomizcd 
and three had had steroid therapy before IFN treatment The 
patient groups also differed in respect to their serum hcmoglo 
bin levels which were lower in group A (median 7 λ g/dl) 
than in group В patients (median 10 0 g/dl ρ < 0 OS) 
Definition of Optimum HIOIORH al Respon ÍP /ПШ/І/І mg Do\is 
of rIF\ alpha 2C Optimum biological response modilying 
doses of rIFN alpha 2( were defined on an individual patient 
basis by evaluation of excretion of the neoptenn marker during 
the time of dose escalation Results obtained with the group В 
HCL patients were compared with those from a previous study 
of metastatic breast cancer eases (28 ) Ranges of dose escalation 
of rIFN alpha 2C differed between these studies being from 
0 1 2 Ox lO^/day for HCl and Irom i-TOx ІОЧІ/day for 
breast cancer patients Results arc demonstrated in Figure 1 
Notably HCL and breast cancer patients did not differ in their 
maximum scrum levels of neoptenn induced by rIFN alpha 
2C In HCL patients IFN doses ranging from 0 2-0 6 x lOOJ 
ITT daily were already sufficient to maximally induce neoptenn 
release in serum In breast cancer patients even IFN dose 
escalation up to 30 x ΙΟ'Ί) daily was not able to further increase 
ordown regulate serum neoptenn concentrations Thus m both 
malignant slates only minimal or moderate doses of exogenous 
IFN alpha 2C were required to obtain an optimal neoptenn 
response in vivo 
Companion of the Clinual EJfuai\ of Comeniional Doses 
Htth Optimum Biolognal Response modifying Doses of rIFN 
alpha 2C in HCL At study entry all 39 patients showed pro 
grcssive disease The daily dose for group A patients was 
2хІОЧІ/ігГ and for group В patients 0 2 0 6 x l 0 4 J / m rIFN 
E 
800 
600 
•400 
200 
p r e ІОЭ 
Z r IFN alphí 2C D»s* (Mio U / D » 4 ) 
Figure 1 EHecl of various doses of rlFN<alpha 2C on neoplerln ex-
cretion m HCL (A) and breast cancer (B) patients Mean values ( ± SE) of 
342 determinations m 21 HCL and 9 breast cancer patients are demon 
strated 
alpha 2C IFN was administered daily for 3 months and there 
after two to three times weekly Only patients who had un 
dergone a minimum of 1 months of therapy were considered 
for analysis Figures 2-6 demonstrate the changes of peripheral 
blood counts in both treatment groups 
All patients responded to IFN treatment regardless of their 
disease or pretreatment status The platelet counts improved 
most rapidly Thrombocytopenia resolved within λ months in 
11 of the 18 group A patients and in 20 of the 21 group В 
patients (Fig 2) Hemoglobin levels also improved during 
treatment with conventional or low doses ol rIFN alpha 2C 
(Fig 3) Notably after 40-52 weeks hemoglobin levels were 
nonnalizcd m all patients treated with low doses of IFN whereas 
in group A the majonty of patients still remained anemie Figure 4 
illustrates the rapid normalization of the peripheral blood leu 
kocytc counts which was caused by clearance of circulating 
HCs Irom the bloodstream in 12 of the 18 group A patients 
and in 15 of the 21 group В patients Concomitantly in both 
patient groups the neutrophil counts markedly increased and 
after 40-52 weeks only one patient in group В had less than 
1000 neutrophils μΙ (Fig 5) Likewise continuous merements 
were observed in the monocyte counts of both treatment groups 
(Fig 6) 
Ihree of the group A patients and 12 cases in group В pre 
scntcd with splenomegaly IFN treatment led lo a reduction ot 
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Figure 2 Changes in plalelel counte of HCL patients treated with 
conventional (upper panel) or low doses (lower panel) or rlFN-alpha-2C 
Bars show the median value and the 25th-75th percentile, the 5th-g5th 
percentile is indicated by vertical lines Significant differences between 
pre- and post-treatment values are indicated 
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Figure 3 Changes in hemoglobin levels of HCL patients treated with 
conventional (upper panel) or low doses (lower panel) of rlFN-alpha-2C 
Bars show the median value and the 25th-75th percentile, the 5th-95th 
percentile is indicated by vertical lines Significant differences between 
pre- and post-treatment values are indicated 
spleen size from a median of 19 cm (range 14 30 cm) to a 
median of 12 cm (range 11-25 cm) in group A and from 18 cm 
(range 13-30 cm) to 13 cm (range 10-28 cm) in group В pa­
tients 
A decrease of the bone marrow HCl was demonstrated 12 
months after initiation of 1F-N therapy in all 39 patients Im 
munohistochemistry proved to be the most sensitive method 
for detection of residual leukemic infiltration in HCL In order 
to compare the effectiveness of both dose regimens on the 
extent of leukemic bone marrow infiltration, nine group A and 
eight group В patients were repeatedly evaluated by immu-
nohistochemical means The results will be reported in detail 
elsewhere (30) As shown in Table 2. the drop of the HCl 
within the first 3-6 months of treatment was more pronounced 
in group A than in group В patients 
Clinical responses were evaluated according to the classifi­
cation scheme of Ratain et al (14) Treatment duration was 
35 weeks (from 26-52) in group A patients and 31 weeks (from 
12-52) in group В patients Overall responses of 100% were 
achieved in both treatment groups According to Ratain et al 's 
entena, two CR one PR, and 15 MR were achieved in group A. 
and one CR. 10 PR. and 10 MR in the less sick 
Comparison of Toxic in ofConvenuonal Do\es and Optimum 
Biological Reïponse-modifwni! Doses of rIFN-alpha 2C in 
HCL During the first month of therapy all group A patients 
developed a flu-like syndrome with myalgia, fatigue and fever 
episodes These symptoms were alleviated by paracetamol, and 
all patients except one were able to continue their normal daily 
activities In one case, discontinuation ot therapy was necessary 
after 3 months due to persistent severe constitutional symptoms 
and depression with suicidal intention Contranly. in group В 
patients, treatment with low doses ol rlhN-alpha-2C were al 
most free of toxicity Only 2 ot 21 patients experienced a mild 
flu-like syndrome during the tirst 2 weeks ot lh\ therapy 
After the first month of treatment, constitutional symptoms, 
such as fever, fatigue, myalgia, and anorexia, requiring symp­
tomatic relief and/or causing a decrease in the performance 
status, occurred in eight (44%) of the group A patients but in 
only one (5%) of the group В cases (Table 4) In six group A 
patients (33%), dose attenuation was required because ot sig­
nificant weight loss (more than 10% ot body weight) Less 
frequent toxicities in group A patients included hair loss (two 
cases) orthostatic hypotension (one case), impolcncy (one case), 
and chemical hepatitis (one case) Myelotoxicity was also more 
pronounced in group A patients In two group A patients gran­
ulocytes dropped below 2(Χ)/μΙ within the first 3 weeks, and 
this was associated with severe infectious complications The 
majority of patients in treatment group A showed transient and 
less severe myelosupprcssion during the first month of therapy 
(F-igs 2-6) The nadir of neutrophil and platelet counts oc 
curred 1-2 weeks after initiation ol IbN therapy Both neutro 
phil and platelet counts recovered by the end of the first month 
In group A patients at week 1-2, neutrophil counts had de­
clined to 0 19Χ ΙΟ'/μΙ (range 0-2 Эх ІО Ь Irom 0 7 (range 
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Figur« 4 Changea In leucocyte counla of HCL patients treated with 
conventional (upper panel) or low dosea (lower panel) ot rlFN-atpha 2C 
Bars show the median value and (he 25th-75th percentile the 5th-95th 
percentile Is indicated by vertical lines Significant dilferences between 
pre- and post-treatment values are indicated 
0 16-2 5 x ΙΟ'/μΙ) betöre treatment and platelet counts to 
52 x 10' μΙ (range 17-245 χ 10 V I ) from 80 x 10' μΐ (range 
10-425 x lOVU Myclotoxicil) ль dose dependent and less 
pronounced in group В tases Neutrophil counts in these pa­
tients only fell from 0 68 χ 10 V i (""ge 0 11-2 6 χ ΙΟ' μΐ) 
before loO 38 Χ ΙΟ'/μΙ (rangeO 22-2 Эх ΙΟ' μΙ) after therapy 
and platelet counts Irom 9 9 x 10' μΙ (range 24-4I6X ΙΟ'/μΙ) 
to 85 Χ ΙΟ'/μΙ (range 27-205 x ΙΟ'/μΙ) (Figs 2, 5) The more 
pronounced myclosupprcssivc effects of higher rIFN alpha 2C 
doses were also documented by a slower rise of hemoglobin 
levels in group A patients with the majorit) ot patients still 
being anemic after 40-52 weeks of treatment (big 3) It should 
be stressed however that in group A cases anemia was more 
pronounced prior to therapy 
DISCUSSION 
The first question addressed in this sludy is whcihcr and to 
what extent therapeutic efficacy ol alpha IFN in HCl can be 
separated trom its toxicity In order to determine optimal doses 
ot an antitumor agent two diflerent strategies can be applied 
First the conventional oncological approach in which maxi 
mum tolerable doses arc gradually reduced and tumor response 
is balanced against toxicity This is a time-consuming approach 
and requires large scale clinical trials which arc difficult to 
perform in a rare disease like HCL Allernalively considering 
IFN as a biological response-modifier, protocols can be de 
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Figure S Changes in neutrophil counts Ol HCL patients treated with 
conventional (upper panel) or low doses (lower panel) of rlFN-alpha-2C 
Bars show the median value and the 25lh-75th percentile Ihe 5th-95th 
percentile is indicated by vertical lines Stgmlicanl differences between 
pre- and post-treatment values are indicated 
signed in which optimum biological response modifying doses 
of IFN arc administered 
In order to define optimal biological IFN doses in vivo the 
ncoptenn marker was chosen because of its sensitivity and ease 
of performance (23) Ncoptenn is a pyrazino-pynmidinc com­
pound derived from GTP It represents an intermediate product 
in the synthetic pathway of bioptenn (23) We have recently 
published that monocytes and macrophages are capable of pro 
ducing ncoptenn when stimulated with IFNs or IFN inducers 
(24) Since ncoptenn is released from monocytes and macro­
phage, which are widely distributed in blood and cxtravascular 
tissues this marker molecule provides a useful tool for the 
assessment of an in vivo IF\ response (23 24 32) Using this 
marker we were able to demonstrate that already minimal IFN 
doses m the order of 0 2 0 6 x lO'U/m'daily s с are sufficient 
to maximally induce ncoptenn release in serum of HCL pa 
tients On the other hand, it should be stressed that no direct 
relationship exists between IFN-mduced neoptenn release and 
the antileukemic activity ol IFN 
Most of the initial HCL studies used alpha-IFN doses close 
to or identical with the maximum tolerable dose of alpha-IFN 
In 1984. Quesada et al first reponed on the successful treat 
ment of seven HCl patients with daily doses of 3 χ lO'U of 
natural alpha IFN (5) A follow up report confirmed these pre 
liminary findings in 52 patients 22 of whom received 3 x 106U 
of leukocyte IFN and the other 30 rIFN-alpha-2A at a dose of 
3 12xl0 6U/day (35) There were 10 complete 30 partial 
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Figure 6 Changes in monocyle counts ot HCL patients treated with 
conventional (upper panel) or low doses (lower panel) ot rlFN-alpha-2C 
Bars show the median value and the 25th-7Sth percentile, the Sth-95th 
percentile is indicated by vertical lines Significant differences between 
pre- and post-treatment values are indicated 
and 10 minor responses among the 52 patients with an overall 
response rate of 96% Golomb et al recently reported the re­
sults of a multi-institutional prospective study of 64 patients 
(18) In this trial, 2 x 106U/nr rIFN-alpha 2B were admims 
tered subcutancously three times per week Three patients (5%) 
achieved CR, 54 (80%) PR, and 9 (14%) showed MR Similar 
results were published by numerous investigators using rlFN-
alpha (6-12) Taken together, response rates were comparable 
for dosages ranging from 3-12 x I06U given intramuscularly 
or subcutaneously daily to three times weekly (14) The initial 
report of Quesada et al indicated that CRs are frequent This 
finding, however, was not confirmed by others Applying Ra-
tain et al s response entena (14) for 376 responses reported 
in the literature (11, 18. 22. 35), only 37 (10%) were found 
to be complete (14) Probably more important, however, is the 
fact that IFN treatment has an excellent palliative effect and 
that virtually all the rcsponders demonstrated normalization of 
peripheral blood cell counts Remission states arc maintained 
at least as long as IFN therapy is continued In our trials, 
comparable results were achieved with a conventional as well 
as a low-dose regimen, with an overall response of 100% in 
both patient groups It should be stresbed. however, that group A 
and group В patients differed with respect to disease stage and 
to the type and intensity of treatment prior to IFN therapy 
(Table 1 ) Therefore, a definite conclusion on the efficacy of 
the conventional and the low-dose IFN regimens cannot be 
drawn from our results 
Virtually all HCL patients treated with conventional doses 
of IFN alpha experienced side effects during therapy ( 14) The 
most frequent IFN-related toxicities are constitutional symp­
toms (14) Less frequent adverse effects are skin disorders, 
local inflammation at the site of injection, gastrointestinal 
symptoms, and central or peripheral nervous system disorders 
(14, 18) In addition, most HCL patients develop transient 
myclosuppression during the first month of treatment (22) 
Other less common toxicities reported are alopecia, gyneco­
mastia, gonadal failure, and chemical hepatitis (6 9 20, 22. 
34, 35) Since most of the side effects of IFN treatment are 
dose-dependent and can be alleviated by dose reduction, it was 
tempting to evaluate the clinical efficacy and toxicity of low 
and presumably atoxic doses of IFN in a highly IFN-sensitive 
malignancy In this report two of our concurrent HCL trials. 
one involving conventional IFN doses and the other a low-dose 
regimen using optimum biological response-modifying doses 
of rIFN-alpha-2C, arc compared Optimum biological re­
sponse-modifying doses defined by induction of the neopterm 
marker (24, 25) were one-tenth to one third of the conventional 
dose range Our results generally confirm the preliminary data 
of a randomized multicenter study reported by Smalley and 
colleagues (36. 37) In this mal, the efficacy and toxicity of a 
conventional dose (2 x lO^U/m2) and a low-dose (0 2 χ lO'LI/ 
m
2) (Wellferon*) regimen were prospectively compared Of 
138 patients, more than 80% completing at least 3 months of 
therapy on either of the dose levels achieved normalization of 
peripheral blood counts Bone marrow responses with a more 
than 50% decrease of HCs were more frequent in the high-
dose therapy group (37) As in our mal, IFN-related toxicity 
was substantially less at the lower dose level (36, 37) Our 
data also substantiate the original report of Porzolt et al (38) 
demonstrating a beneficial effect of low doses of IFN alpha in 
three patients with advanced HCL and severe thrombocyto-
Tsble 4 Nonhemalologlcal Side Effecls In Hairy Cell Leukemia Patients Treated with riFN-alpha-2C 
Symptoms 
•Temperature 38"C 
•Pain 
'Gastrointestinal disorders 
'Fatigue 
Hair loss 
Neurological disorders 
Hypotension 
Impolency 
Chemical hepatitis 
Conventional Dose (Group A) 
η - 18 
Week l 4 
1 6 
13 
β 
5 
0 
0 
0 
0 
0 
After Week 4 
β 
13 
β 
4 
2 
2 
1 
1 
1 
No ol Patients 
Week ι 
2 
1 
0 
0 
0 
0 
0 
0 
0 
Low Dose (Group B) 
η - 21 
-4 Alter week 4 
0 
1 
0 
0 
0 
0 
0 
0 
0 
'Constitutional symptoms requiring symptomatic relief and or causing a decrease of the Karnovsky status by ±25% 
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penta We thus conclude Ihdt (a) low doses of alpha IFN pro­
vide excellent disease palliation in the majority of HCL patients 
irrespective at disease stage and pretreatment status (b) higher 
doses of alpha IFN exert a more pronounced antileukemic ef 
feet, as documented by a more rapid and marked decrease of 
leukemic bone marrow infiltrates in patients treated with con­
ventional doses and (c) that serious side effects including mye­
lotoxicity can be almost completely avoided by applying a low 
dose IFN regimen 
What are the practical implications of our observation ' The 
finding of an almost atoxic therapeutic modality is of particular 
importance since the majority of HCL patients are not cured 
by alpha IFN therapy Low doses of alpha-IFN ranging from 
0 2 - 0 6 x 10 6 U/m' provide an alternative for further treatment 
of HCL patients who develop toxic side effects 1 ow dose 
alpha IFN treatment should also be considered for primary 
treatment of HCl patients with advanced age or with severe 
cytopenia who arc known to develop serious toxicity when 
treated with higher doses of IFN Moreover, low dose IFN 
might represent the treatment of choice for long term mainte 
nance therapy of HCL patients in whom a complete remission 
cannot be achieved Lastly low dose IFN treatment of HCl 
provides a cheaper alternative to the conventional IFN dose 
regimens 
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CHAPTER 4 
Treatment of hairy cell leukemia with low dose interferon: 
reduction of side effects and preservation 
of therapeutical efficacy. 
M.J.B.P. Abegg-Werter, M.J.J.T. Bogman, J.M.M. Raemaekers, 
B.E. de Pauw, С. Haanen 
Submitted 
ABSTRACT 
Forty consecutive patients with hairy cell leukemia were treated 
with recombinant interferon-α. The first 19 patients received 
interferon-Oîс 5 χ 10е units daily subcutaneously for 12 weeks, 
followed by maintenance treatment of 5 χ 10е units twice weekly 
(18 patients évaluable). The other 21 patients were treated with 
interferon-агA, either in a dose of 3 χ lO'units thrice weekly (6 
patients, 5 évaluable),or 1,5 χ lO'units thrice weekly (15 
patients, all évaluable). Hematological remissions were achieved 
in 78%, 80% and 60% of the cases respectively. Reduction of 
hairy cells in the bone marrow was obtained in 11 out of 12 
patients in the high dose group and 7 out of 8 in the lowest dose 
group. A reduction in spleen size to normal was obtained in all 
patients within 3 months. The reappearance of granulocytes and 
monocytes was delayed in the group with the lowest dose of 
interferon without an increase of infection rates. Side effects 
like fever, myalgia and fatigue appeared to be related to the 
dose and were negligible at the lowest dose. 
We conclude that interferon-α in a dose of 1,5 χ 10*units thrice 
weekly is effective in the treatment of hairy cell leukemia with 
reduced side effects in comparison to the traditional dose 
schedules. 
ADDENDUM 
The 19 patients of group A are also part of the patients 
described in Chapter 2 
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INTRODUCTION 
Hairy cell leukemia (HCL) is a systemic neoplastic disease 
characterized by slow proliferation of mononuclear cells 
infiltrating the spleen and bone marrow and to a lower extent the 
liver and lymph nodes1 . HCL is generally associated with varying 
degrees of pancytopenia2. Until the introduction of interferon-α 
no effective therapy was available. Splenectomy induces an 
apparent remission in 70-90 % of the patients, though with a 
variable remission duration3-β. The results of chemotherapy after 
splenectomy are poor and often connected with longterm aplasias, 
life-threatening infections and rarely with longstanding 
improvement»-9. Since the encouraging results with interferon-α 
reported by Quesada et al. in 198410 many investigators have 
corroborated the effectiveness of recombinant interferon-α11- 1 3 . 
However, its use is often accompanied by substantial side effects 
like apathy, fatigue and anorexia, which may interfere the 
quality of life. Earlier studies indicated that lowering the dose 
may reduce side effects without a decrease in the response 
rate14-1». In the present study, performed in collaboration with 
18 Dutch centers, we compared the results of the treatment of HCL 
with different doses of recombinant interferon-α with special 
emphasis on the occurrence of side effects. 
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MATERIAL AND METHODS 
The diagnosis of HCL was based on bone marrow histology and/or 
spleen histology and confirmed by tartrate resistent acid 
phophatase staining on lymphocytes of peripheral blood, bone 
marrow or imprints of histological material. In some cases 
surface immunoglobulin staining or electronmicroscopy was 
performed to confirm the diagnosis. Patients were enrolled when 
the diagnosis HCL was histologically confirmed and progressive 
disease, resulting in bone marrow insufficiency, or recurrent 
infections was documented. Progressive disease was present if 
hemoglobin (Hb) fell <. 7,3 mmol/1, granulopenia was <. 0,5 χ 10s/1 
or thrombopenia was <. 70 χ 10'/1. All histological material taken 
prior to treatment was revised by one of us (MJB) to confirm the 
diagnosis HCL and to estimate the extent of the disease in the 
bone marrow. The percentage of hairy cell infiltration was 
estimated semi-quantitatively in proportion to the total cell 
population. 
Interferon 
Recombinant interf егоп-аг с (rlFN-otzc ) (Berof orR ) was kindly 
supplied by Boehringer Ingelheim, Alkmaar, The Netherlands, in 
ampoules of 5 χ 10' units. Recombinant interferon-aaA (rlFN-
агA)(RoferonR, Hoffman-La Roche) was supplied on prescription in 
ampoules of 3 χ IO6 units. 
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Treatment scheme 
Nineteen patients were treated with rIFN-azc 5 χ 10e units daily 
subcutaneously (se) as an induction therapy for 12 weeks, 
followed by a maintenance therapy of 5 χ IO6 units twice weekly 
(group A). Six patients were treated with rlFN-otzA 3 χ IO6 units 
thrice weekly sc (group B). Fifteen patients were treated with 
rIFN-a2A 1,5 χ IO6 units thrice weekly sc (group C). Interferon 
was administered by the patients themselves on an out-patient 
base. 
Evaluation 
Pretreatment evaluation included physical examination, 
determination of complete blood cell counts, liver and kidney 
function tests, bone marrow biopsy and echography of the spleen. 
Follow-up evaluation of blood cell counts, liver and kidney 
function tests were performed weekly in the first month, 
fortnightly in the second and third month, monthly thereafter. 
Echography to estimate the spleen size was performed at three 
months interval. In case of hematological remission, repeat bone 
marrow biopsies of the iliac crest were scheduled after 3, б and 
12 months of treatment, to assess the reduction of hairy cell 
infiltration. Side effects were put forward by the patient 
spontaneously and/or asked for by the physician. Adverse effects 
and infections were scored by the treating physician according to 
the listing in the protocol (see Table 4). 
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D e f i n i t i o n s of r e s p o n s e w e r e : 
Complete r e m i s s i o n (CR): e s t i m a t e d number of h a i r y c e l l s i n 
t h e bone marrow b i o p s y <. than 5% w i t h Hb > 7 , 3 mmol/l, 
g r a n u l o c y t e s > 1,5 χ 1 0 ' / 1 , t h r o m b o c y t e s > 100 χ 1 0 ' / 1 and 
n o r m a l i z a t i o n of i n i t i a l organomega ly i f a p p l i c a b l e . 
H e m a t o l o g i c a l r e m i s s i o n (HR): as c o m p l e t e r e m i s s i o n but w i t h 
p e r s i s t a n c e of > 5% h a i r y c e l l s i n t h e bone marrow b i o p s y . 
Minor r e s p o n s e (MR): Hb > 7 , 3 mmol/l or g r a n u l o c y t e s > 1,5 χ 
1 0 « / 1 or t h r o m b o c y t e s > 100 χ 1 0 » / 1 . 
No r e s p o n s e (NR): no change i n h e m o g l o b i n , g r a n u l o c y t e s or 
t h r o m b o c y t e s i s o b s e r v e d . 
Table 1. Patients character i s t ics . 
group F/M1 age spien- Hb thrombo's granule's pancyto 
(years) ectomy (mmol/l) (x IQVl) (x IQVl) penia2 
range mean <7,3 <70 <0,5 
A3 2/17 34-79 57 63% 84% 42% 37% 16% 
(N=19) 
B« 0/6 43-77 56 33% 83% 17% 17% 17% 
(N=6) 
C» 4/11 37-62 48 47% 80% 60% 53% 47% 
(N=15) 
1) F=female, M=male 
2) pancytopenia: Hb < 7,3 mmol/l, thrombocytes < 70 χ lOVl and granulocytes < 
0,5 χ 10»/1 
3) group A: treated with interferon-azc 5 χ IO6 units daily 
4) group B: treated with interferon-a2A 3 χ 10 6 units thrice weekly 
5) group C: treated with interferon-a2A 1,5 x 10 e units thrice weekly 
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RESULTS 
Forty patients (6 female, 34 male) were enrolled from October 
1984 up to January 1989. Patient characteristics are summarized 
in Table 1. The groups were not completely balanced due to a 
change in treatment policy, consisting of omittance of 
splenectomy as first treatment for patients induced in group C, 
because interferon-α was generally accepted as treatment for HCL. 
Patients in group С were younger and had more pronounced 
pancytopenia. Two patients (one in group A and one in group B) 
were not évaluable for response because they died during the 
first month of treatment, one of septicemia, the other of 
pneumonia. 
Whole blood counts 
The results of the blood counts are summarized in Fig. 1. 
Reduction of the dosage of interferon was not associated with 
a slower recovery rate of hemoglobin and thrombocyte counts. 
Recovery of the granulocytopenia appeared to be delayed. Fifty 
percent of the patients had achieved normal blood counts after 5 
months of treatment in group A, after 4 months in group В and 
after 5 months in group С (Table 2). Monocyte counts tended to be 
lower in group В and С than in group A. However, this difference 
4 
did not reach statistical significance. 
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о 
80 
60 
40 
20 jr granulocytes 
> 1,5 χ lOVl 
Τ if—й-
•¿г • — * _ / * * — * — * 
• — · 
i r — * thrombocytes 
> 100 χ 109/1 
monocytes 
> 0,2 χ 10V1 
0 1/2 1 2 3 4 5 6 9 12 0 1/2 1 2 3 4 5 6 9 12 
months of treatment 
Figure 1. Hematological eva luat ion of p a t i e n t s with hairy c e l l 
leukemia t r e a t e d with d i f f e r e n t doses of i n t e r f e r o n - o . 
• : group A, т : group B, -k : group C. 
(For d e f i n i t i o n of the groups see Table 1 ) . 
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Table 2. Comparison of different doses interferon-α on the 
median interval to response of different parameters. 
group A1 
(N=18) 
group B1 
(N=5) 
group C1 
(N=15) 
median interval from start of interferon-α 
treatment to recovery of 
Hb granulocytes thrombocytes spleen 
>7,3 mmol/1 >1,5 m χ IO9/1 >100 χ 109/1 normalization 
5 months 
4 months 
3 months 
2 months 
3 months 
5 months 
2 weeks 
4 weeks 
<3 months 
(N=7) 
<3 months 
(N=3) 
<3 months 
(N=8) 
1) for definition of the groups see Table 1. 
Spleen 
Normalization of the spleen size was seen in all patients within 
3 months, independent of the treatment scheme. There was no 
difference in the recovery time of the blood counts between the 
patients with and without previous splenectomy. 
Bone marrow biopsies 
In nearly all patients the bone marrow biopsies taken before 
treatment showed a diffuse infiltration of hairy cells, similar 
in the three treatment groups. Reduction of hairy cells from the 
bone marrow was obtained in 10 out of 12 patients of group A and 
7 out of 8 patients in group С who were evaluated by consecutive 
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Figure 2. Percentage of hairy cell infiltration in bone marrow 
biopsies in patients treated with different doses of interferon-
σ. (For definition of the groups see Table 1). 
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biopsies (Fig. 2). Group В was omitted in view of the limited 
number of patients with consecutive biopsies (N=3). The scheduled 
bone marrow biopsies were not repeated in all patients due to 
patients' refusal in some cases and protocol violation in other 
cases. 
Response 
Complete remission, with decrease of hairy cell infiltration in 
the bone marrow to less than 5 %, was obtained in 2 out of 18 
patients in group A: in one after 1 and in the other after 12 
months of treatment. Hematological remission rate was slightly 
lower in group С after 3 months of treatment. This difference 
disappeared after 6 months of treatment (Table 3). During 
treatment a shift from minor response to HR due to normalization 
of all blood counts was observed. Only in one patient in group В 
minor response was persistent up to 12 months of treatment. This 
patient obtained a hematological remission after increment of the 
dosing frequency to 5x weekly. No decrease in response rate was 
present in patients treated with the lowest dose interferon 
(group C) as compared to patients treated with the conventional 
dose interferon (group A)(Table 3). 
Infections 
In group A one patient died during the first month of treatment 
due to septicemia. Also some minor, non-life-threatening 
infections like common cold (lx), transient flu-like disease 
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Table 3. Response in patients with hairy cell leukemia treated 
with different doses of interferon-α. 
Group N 2 Duration of therapy 
3 months б months 
HR3 (%) MR4 (%) HR3 (%) MR4 (%) 
A1 18 6' (33) 11 (61) 14' (78) 4 (22) 
B1 5 2 (40) 2 (40) 4 (80) 1 (20) 
C1 15 3 (20) 12 (80) 9 (60) 6 (40) 
1) for definition of the groups see Table 1. 
2) N: number of évaluable patients 
3) HR: hematological remission 
4) MR: minor response 
5) Two patients with complete remission are included 
(lx), staphylococcal infection of the skin (lx) and mycosis of 
the inguinal skin (lx) were encountered. In group В one patient 
had a fatal pneumonia during the first month of treatment. No 
other infections were noticed in this group. In group С one 
patient was treated successfully for a septicemia caused by 
Strep. hemolyticus, originating from an infected infusion 
insertion site during the second week of treatment. Despite the 
antiviral activity of interferon several viral infections were 
encountered in group C: common cold 2x, influenza A lx, herpes 
labialis lx and Epstein Barr viral infection lx. 
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Side effects 
A reduction of side effects was evident in the patients who 
received the lower doses of interferon-α (Table 4). In group A 
two patients, who previously had suffered from a mental 
depression, had a relapse of depression during interferon 
therapy. The depression subsided after discontinuation of 
interferon. In 2 patients treated with 1,5 χ 10e units 
interferon-α thrice weekly, a further reduction to 0,75 χ IO6 and 
1,0 χ 10s units thrice weekly was necessary because of severe 
fatigue and itching, disappearing after dose reduction. Both 
patients showed persistent response after dose reduction. Four 
out of 15 patients treated with rIFN-a2A 1,5 χ 10e units thrice 
weekly showed local irritation at the injection site. This was 
not seen in the other patients treated with either rIFN-a2c or 
with rIFN-asA in a dosage of 3,0 χ IO6units thrice weekly. No 
relation with badge number or injection technique was found. No 
disturbances of kidney and liver function were noticed. 
DISCUSSION 
Our study shows that treatment of hairy cell leukemia with the 
lower dose of 1,5 χ 10е units interferon-α results in eventual 
response rates comparable to those obtained by conventional 
doses, even in spite of the worse pretreatment parameters of the 
patients treated with the lowest dose interferon-α. Likewise no 
increased incidence of life-threatening infections was noticed in 
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Table 4. Occurrence of side effects and infections in patients 
with hairy cell leukemia treated with different doses 
of interferon-α. 
Side effects 
fever, chills 
myalgia 
fatigue 
anorexia, nausea 
headache 
hair loss 
paresthesia 
itching 
mental disturbances 
impotentia 
premature beats 
eczema 
local irritation 
at injection site 
group A1 
N=18 
12 
11 
11 
8 
4 
3 
3 
2 
2 
1 
(66%) 
(61%) 
(61%) 
(44%) 
(22%) 
(17%) 
(17%) 
(11%) 
(11%) 
( 6%) 
group B1 
N=5 
1 
3 
2 
1 
2 
1 
1 
1 
1 
(20%) 
(60%) 
(40%) 
(20%) 
(40%) 
(20%) 
(20%) 
(20%) 
(20%) 
group C1 
h 
6 
6 
4 
1 
3 
1 
2 
2 
4 
1=15 
(40%) 
(40%) 
(27%) 
( 7%) 
(20%) 
( 7%) 
(13%) 
(13%) 
(27%) 
Number of infections 
bacterial 2 1 1 
viral 2 - 5 
mycosis 1 - -
1) for definition of the groups see Table 1. 
the lowest interferon-α group, although the recovery of 
granulocytes and monocytes was delayed. The reduction of the dose 
of interferon was accompanied by a reduction of side effects. In 
the patients treated with the lower dose of interferon, no 
complete remissions were obtained. Conventional doses of 
interferon up to of 5 χ 10' units daily can induce "complete 
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remissions" with less than 5 % hairy cells in the bone marrow 
biopsies. However, the clinical significance of these complete 
remissions is doubtful since discontinuation of interferon 
results sooner or later in relapses which necessitate retreatment 
1 6
>
1 7
. Considering these data, the limited number of bone marrow 
biopsies during follow-up due to patients' refusal or protocol 
violation may be explained by the lack of consequences for 
further treatment. Additional studies are needed to explore the 
question whether intermittent high dose interferon with 
substantial side effects is preferable to continuous low dose 
interferon with minor side effects. Further reduction of the 
dosage scheme to 1,0 χ 10e units interferon weekly may be 
inappropriate1 β^ 1 β. Possibly the optimal dose of interferon can 
be titrated by measurement of the neopterin excretion, a marker 
for macrophage activation, in the urine20. 
Deoxycoformycin is another effective drug in the treatment of 
hairy cell leukemia with high complete remission rates (60%-
90%)2ΐ,22
>
 Unfortunately treatment with deoxycoformycin induces 
immunosuppression with increased infection rates 2 3- 2 4. Moreover, 
longterm follow-up is not available. Randomized trials are now 
being performed comparing deoxycoformycin to interferon-α as 
first line treatment in hairy cell leukemia. 
Antiviral activity of interferon-o is achieved with high doses 
interferon-a2»-27.The presence of serologically proven viral 
infections in the low dose interferon group suggests a less 
67 
outspoken antiviral effect in these patients. It has been 
demonstrated that low doses of interferon induce a more enhanced 
immune response than larger doses28. This may explain the cases 
of local irritation observed in group C, although a connection 
with the type of recombinant interferon used, interfегоп-агA 
versus interfегоп-агс, can not be ruled out. 
In conclusion we have shown that treatment of hairy cell leukemia 
with low dose interferon is feasible and that the frequency of 
side effects is reduced by such a strategy, without loss of 
therapeutic efficacy or increment of infection rates . 
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CHAPTER 5 
Recombinant interferon-alpha, but not interferon-gamma 
is effective therapy for essential thrombocythemia. 
M.J.B.P. Abegg-Werter, J.M.M. Raemaekers, B.E. de Pauw, C.Haanen 
Blut 1990; 60: 37-40. 
ABSTRACT 
Recombinant interieron-# (rIFN-tf) with a starting dose of 0,5 
mg 3x weekly sc, was administered to б patients with 
essential thrombocythemia (median thrombocyte count 1172 χ 
10'/1, range 602 - 1564) . Four of them had received 
alkylating agents previously. Hematological remission, 
defined as a decrease in thrombocyte counts to <. 350 χ 10*/1, 
was observed in none of these patients. Subsequently 4 of 
these 6 patients, supplemented by 2 others were treated with 
interfегоп-агс at a dose of 5x 10' U daily sc. Five patients 
showed hematological remission. In case of hematological 
remission the interferon-o dosis was reduced to 5x and 
thereafter to 3x weekly 5x IO6 U. During an observation 
period ranging from 12 - 41 weeks thrombocyte counts remained 
normal in all patients. Side effects were mild and consisted 
of fever, myalgias, malaise and itching occurring mainly 
during the first month of treatment. No dose adaptation was 
required. The patients treated previously with rlFN-tf 
experienced the side effects from this drug less tolerably 
than those from the α-compound. These observations suggest 
that recombinant interferon-α may be an effective drug in 
treating essential thrombocythemia resulting in a sustained 
response. 
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INTRODUCTION 
Thrombocythemia may be a concomitant sign in 
myeloproliferative disorders like polycythemia vera, chronic 
myelogenous leukemia, and myelofibrosis. Essential 
thrombocythemia (ET) is defined as an isolated abnormal 
proliferation of megakaryocytes in the bone marrow. The 
Polycythaemia Vera Study Group has established strict 
diagnostic criteria1. Treatment of ET requires balancing 
putative drug toxicity versus the risk of the occurrence of 
thrombo-embolic and/or hemorrhagic complications. In mild 
symptom-free cases anti-aggregant therapy with acetyl-salicyl 
acid may suffice2·э, whereas a platelet count of over 1000 χ 
109/1 or the occurrence of vascular complications warrant 
antiproliferative therapy. Control of thrombocyte counts with 
occasionally prolonged remissions can be obtained by using 
alkylating drugs such as busulfan, chloorambucil and 
melfalan4"8. These drugs are known to be inducers of 
secondary malignancies and may cause unexpectedly prolonged 
bone marrow hypoplasia7. Interferon, a substance with 
immunomodulative and antiproliferative properties8-9, may 
offer an alternative in view of its efficacy in 
myeloproliferative diseases. In 1983 Talpaz et al. reported 
the results of leukocyte interferon-α in patients with 
chronic myelogenous leukemia-associated thrombocythemia10. 
The efficacy of interferon-ot in thrombocythemia has been 
corroborated by others during recent years11·ι2. In vitro 
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interferon-u appeared to be even more powerful than 
interferon-α13. Since a phase I study revealed the potency of 
interferon-rf in controlling thrombocythemia in CML1* , we 
investigated in an open phase II study the efficacy and 
toxicity of recombinant interferon-^ and -a in patients 
suffering from essential thrombocythemia. 
MATERIALS AND METHODS 
Patient population 
All patients met the criteria of the diagnosis of essential 
thrombocythemia as stated by the Polycythaemia Vera Study 
Group: (1) platelet counts > 600 χ 10»/1; (2) Hemoglobin <. 
8,0 mmol/l or normal red cell mass (males < 36 ml/kg, females 
< 32 ml/kg); (3) stainable iron in marrow or failure of iron 
trial (< 1 mmol/l rise in hemoglobin after one month of iron 
therapy); (4) no Philadelphia chromosome; (5) collagen 
fibrosis of marrow absent, or less than 1/3 biopsy area 
without both splenomegaly and leuko-erythroblastic reaction; 
(6) no known cause for reactive thrombocytosis [12]. Neither 
thrombo-embolic complications nor serious hemorrhagic 
diathesis were present. All patients were without any 
treatment for at least 6 weeks. Oral informed consent was 
obtained. 
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Interferons 
Recombinant interferon-^ (rIFN-ij) was supplied in ampoules of 
0.5 mg lyophilizate, of >. 98% purity and a specific activity 
of 2 χ 107 U/mg. Recombinant interf егоп-агс (rlFN-otzc), 
Berofor, was supplied in ampoules of 5x IO6 U lyophilizate, 
of >. 98% purity and a specific activity of 3,2 χ 10е U/mg. 
Both interferons were kindly provided by Boehringer Ingelheim 
BV, Alkmaar, The Netherlands. 
Treatment scheme 
rIFN-tf (0.5 mg) was administered thrice weekly subcutaneously 
for three months. If no response was obtained, even after 
increasing the treatment frequency to 0.5 mg rIFN-tf daily, 
patients were eligible for treatment with rIFN-aac after a 
minimal interval of 6 weeks. rIFN-ozc was administered at a 
dosage of 5x IO6 U daily subcutaneously, with a reduction in 
frequency in case of hematological remission (platelets <. 350 
χ 109/1) to 5- and 3-times weekly. The interferon injections 
were administered by the patients themselves on an outpatient 
basis. Side effects were treated with paracetamol. 
Evaluation 
Pretreatment evaluation included physical examination, 
determination of complete blood counts, liver and kidney 
function and urine analysis, serum iron and iron binding 
capacity. Bone marrow aspiration was performed for 
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morphological and cytogenetic analysis. Bone marrow biopsy 
was performed for histological analysis. Size of the spleen 
was confirmed by echography. In case of suspicion of the 
presence of polycythemia vera red cell mass was assessed. 
Follow-up evaluation of blood counts was performed 
fortnightly for the first 3 months of treatment, followed by 
monthly evaluations thereafter. 
Definition of response were: 
- Hematological remission (HR): decrease of thrombocyte counts 
to 1 350 χ 10V1. 
- Partial remission (PR): reduction of thrombocyte counts to 
350 - 600 χ 10»/1. 
- No response (NR): platelet counts remained > 600 χ 10'/1. 
RESULTS 
Eight patients (5 female, 3 male) were enrolled in this 
study. Their characteristics are summarized in Table 1. Not 
having responded to rlFN-tf 2 patients refused treatment with 
rIFN-a2c because of the side effects they had experienced 
with rIFN-tf. In all 6 patients treated with rIFN-tf an early 
reduction of thrombocyte counts of 163-407 xlOVl was 
observed within a few weeks, followed by a plateau phase. 
None of the patients reached normalization of the thrombocyte 
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counts (Fig 1). Increasing the frequency to 0.5 mg rIFN-tf 
daily did not induce a further reduction in thrombocyte 
counts. All patients treated with rIFN-azc achieved a 
considerable reduction of thrombocyte counts: 5 patients 
showed HR after 2, 3, 3, 7 and 21 weeks of treatment 
respectively. The one remaining patient showed a steady 
reduction of thrombocyte counts from 1247 to 691 χ 10'/1 
during 20 weeks of treatment: the pattern of steady reduction 
of thrombocyte counts was similar to that of the patient who 
attained HR after 21 weeks of treatment (Fig 2). In the 5 
Table 1. Clinical data. 
pat 
1 
2 
3 
4 
5 
6 
7 
8 
sex 
F/M 
F 
M 
F 
M 
F 
F 
F 
M 
age 
years 
45 
36 
38 
48 
42 
63 
29 
42 
previous 
therapy 
Melphalan 
160 
1246 
254 
— 
160 
— 
240 
1204 
mg 
mg 
mg 
mg 
mg 
mg 
platelet counts (xlC 
Pre - per Pre -
rIFN-tf rIFK 
697 
602 
1172 
1564 
650 
1202 
- 460 
- 439 694 
- 765 1103 
- 1332 1247 
- 440 732 
- 926 
754 
612 
l'/l) 
per 
Γ-σ 
-
- 276 
- 302 
- 691 
- 327 
-
- 247 
- 330 
F=female, M=male, pre=pretreatment value, per=lowest value 
during treatment. 
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patients with HR a reduction of injection frequency was 
carried out until thrombocyte counts tended to increase 
above 400 χ 10*/1. Reduction of injection frequency to 3x 
weekly was feasible in all patients. HR was maintained during 
12* , 13* , 26* , 39* , 41+ weeks respectively. 
Side effects 
Severe subjective side effects like persistent fever, 
malaise, myalgia and headaches were noticed in all patients 
treated with rIFN-tf. All side effects subsided after 
discontinuation of treatment. With rlFN-o^c mild side effects 
were noticed such as myalgias, fever, malaise and itching, 
appearing mainly in the first month of treatment and most 
being dose-dependent (Table 2). In the 4 patients treated 
consecutively with rlFN-tf and rIFN-агс side effects of 
interferon-^ were less tolerable than those of interferon-α. 
Table 2. Side effects. 
persistent fever 
fatigue,malaise 
myalgia 
headache 
anorexia,nausea 
depression/agitation 
diarrhoea 
coughing 
hair loss 
itching 
rIFN-tf 
(N=6) 
5 
5 
4 
4 
2 
2 
1 
1 
1 
1 
rIFN-a2c 
(N=6) 
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Figure 1. Ef fect of recombinant in ter feron-^ on 
the thrombocyte counts of 6 p a t i e n t s su f fer ing 
from e s s e n t i a l thrombocythemia. 
2 4 6 8 10 12 14 
weeks of treatment 
Figure 2. Ef fect of recombinant in ter feron-α on 
the thrombocyte counts of б p a t i e n t s su f fer ing 
from e s s e n t i a l thrombocythemia. 
DISCUSSION 
Currently there is no convincing evidence that lowering the 
thrombocyte counts in asymptomatic patients with 
thrombocytosis is of benefit15. The situation is quite 
different in patients with active bleeding or thrombo-embolic 
complications. In these patients reduction of thrombocyte 
counts should be aimed for16. Although the results of in 
vitro studies and case reports have suggested otherwise13·14, 
rlFN-ïf showed little efficacy, despite pronounced toxic side 
effects in all patients. The possibility of undertreatment 
was ruled out by increasing treatment frequency from three 
times weekly to daily. This procedure did not render any 
additive effect. After treatment of 6 patients with rIFN-d we 
decided to discontinue the study because of a putative lack 
of efficacy and the presence of subjective and objective side 
effects such as persisting fever, fatigue, myalgias and 
headaches in all patients, interfering their daily life 
activities. In contrast rIFN-a2c proved to be more 
efficacious in the treatment of essential thrombocythemia. 
These findings corroborate recently published data ιτ-21. 
Unanswered are the questions regarding long term side effects 
of rIFN-a and its potency of curing as in some CML cases22. 
Presently, all patients in this study need maintenance 
therapy with rIFN-a2c. To the present, all side effects 
noticed are reversible after discontinuation and we did not 
encounter long-term irreversible side effects, in contrast to 
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alkylating drugs, known as possible inducers of unexpectedly 
prolonged hypoplasia, lungfibrosis, pigmentations of the 
skin, and secondary malignancies23. rIFN-агс is an effective 
treatment for essential thrombocythemia with tolerable 
subjective side effects, especially after dose reduction. 
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CHAPTER б 
Recombinant human interferon-α induced cytoreduction 
in chronic myelogenous leukemia. 
M. Werter, T. de Witte, J. Janssen, В. de Pauw, С. Haanen 
Blut 1988; 56: 209-212. 
ABSTRACT 
Fourteen patients with Ph'-chromosome positive chronic myelo­
genous leukemia (CML) in first chronic phase were treated 
with recombinant interferon-ctzc · Interferon-aac 5 to 10 χ IO6 
U dd s.c. was given for 12 weeks as an induction therapy. 
Maintenance treatment consisted of interfегоп-агс 5 χ IO6 U 
twice weekly s.c. Two patients (14%) attained a complete 
clinical remission and 6 (43%) a partial remission, 3 of whom 
developed progressive disease during maintenance therapy. A 
complete disappearance of Ph'-chromosome was achieved in 1 
patient. All patients had a more than 45% initial decline of 
the leukocyte count. Four out of 10 patients with an 
initially enlarged spleen demonstrated reduction in spleen 
size. Influenza-like symptoms, anorexia, nausea, weight loss 
and fatigue were common side effects. 
Interferon-α is active in CML but additional clinical 
investigations are warranted to assess more precisely the 
therapeutic value of the interferons in this disease. 
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INTRODUCTION 
The average survival of patients with chronic myelogenous 
leukaemia (CML) has not improved substantially over the last 
30 years, despite the availability of cytostatic agents such 
as busulphan and hydroxyureum1 - 3. Longterm eradication of the 
Ph'-chromosome and potential cure is only possible in a 
subgroup of patients in first chronic phase by means of 
allogeneic bone marrow transplantation (BMT). However, this 
procedure is limited to patients below 50 years of age with a 
HLA-identical donor4-s. So far no potentially curative 
treatment is available for over 80% of the patients. Recently 
o-interferon has been used experimentally to treat patients 
with CML resulting in a remarkable reduction of Ph'-
chromosome in some patients7. This paper describes the 
results of a multicenter trial on the value of interferon-α 
therapy in 14 Ph'-chromosome positive CML patients. 
MATERIAL AND METHODS 
Patient population 
All patients were in first chronic phase of a Ph'-chromosome 
positive CML without signs of acceleration or blastic 
transformation. 
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Interferon 
Recombinant interferon-aze (rIFN-a2с)(Berofor) was kindly 
supplied by Boehringer Ingelheim BV, Alkmaar, The 
Netherlands, in ampoules of 5 χ IO6 units lyophilizate, with 
>_ 98% degree of purity and a specific activity of 3,2 χ 10е 
units/mg. 
Treatment scheme 
Induction treatment consisted of rIFN-azc 6 weeks 5 χ 10е 
units daily sc and 6 weeks 10 χ IO6 units daily, administered 
by the patients themselves on an outpatient basis. If after 6 
weeks a deterioration of leukocyte count and/or spleen size 
was noticed, the treatment with rIFN-azcwas ended. In case of 
stable disease or progressive disease after a 12 weeks 
induction period the treatment with rIFN-azc was also ended. 
Maintenance treatment consisted of rIFN-a2c twice weekly sc. 
Evaluation 
Pretreatment evaluation included physical examination, 
determination of complete blood counts, liver and kidney 
function and measurement of Vit Bi 2, LDH, LAP-score. Bone 
marrow aspiration was performed for conventional 
investigation and cytogenetic analysis. Size of the spleen 
was confirmed by echography. Follow-up evaluation of the 
blood counts was performed fortnightly. Echography was 
repeated at 6 week intervals until maintenance therapy was 
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instituted. Bone marrow aspiration and cytogenetic analysis 
were repeated in case of hematological remission (HR). 
Definitions of response were: 
Complete remission (CR): complete disappearance of signs 
and symptoms with normalization of blood values, blood and 
bone marrow smears with complete disappearance of the Ph'-
chromosome. 
Hematological remission (HR): identical to complete 
remission but with persistance of the Ph'-chromosome. 
- Partial remission (PR): decrease in leukocyte count of more 
than 50%, without increase in spleen size. 
Stable disease (SD): decrease of less than 50% of the 
leukocyte count without increase in spleen size. 
Progressive disease (PD): increase of leukocyte count 
and/or spleen size and/or emergence of acceleration or 
blastic transformation. 
RESULTS 
Fourteen patients (8 male, 6 female) were enrolled in this 
study from February 1985 until December 1986. The clinical 
data are summarized in Table 1. Seven patients had been 
treated previously with busulfan or hydroxy-ureum for an 
median of 6 months (range 1 - 27 months). The interval 
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b e t w e e n p r i o r c y t o s t a t i c s and rIFN-агс was a t l e a s t 6 w e e k s . 
E v a l u a t i o n a f t e r 6 weeks 5 χ IO6 u n i t s rIFN-azc r e s u l t e d i n 
PR i n 7 p a t i e n t s (50%), SD i n 6 p a t i e n t s (43%) and PD i n 1 
p a t i e n t , who was t a k e n o f f s t u d y . Dur ing t h e i n d u c t i o n p e r i o d 
1 p a t i e n t e x p e r i e n c e d s e v e r e s i d e e f f e c t s such a s a n o r e x i a , 
n a u s e a and f a t i g u e and was t a k e n o f f s t u d y a f t e r 7 weeks o f 
t r e a t m e n t . Twelve p a t i e n t s were é v a l u a b l e a t t h e end of t h e 
i n d u c t i o n p e r i o d : 1 HR, 7 PR, 1 SD and 3 PD were r e g i s t e r e d . 
One p a t i e n t i n p a r t i a l r e m i s s i o n was t a k e n o f f s t u d y b e c a u s e 
of an e x t e n s i v e b l e e d i n g i n t h e p s o a s m u s c l e . Seven p a t i e n t s 
Table 1. Clinical data. 
pat sex age time1 prex VBCC (x 109/1) spleen s i ze BCM Comments 
F/M years months + / - PTV LVR pre» EOT 
1 
2 
Э 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
F 
M 
F 
M 
M 
И 
и 
M 
и 
F 
H 
F 
F 
F 
19 
49 
38 
62 
48 
45 
32 
43 
40 
46 
50 
63 
29 
28 
7 
17 
10 
1 
0 
0 
11 
1 
29 
0 
0 
0 
1 
18 
+ 
+ 
+ 
-
-
-
+ 
-
+ 
-
-
-
+ 
+ 
114 
88 
63 
97 
97 
173 
95 
213 
42 
374 
197 
103 
332 
59 
- 19 
- 12 
- 4 
- 16 
- 21 
- 9 
- 43 
- 116 
- 16 
- 20 
- 99 
- 6 
- 107 
- 31 
(12) 2 
(16) 
(10) 
( 6) 
( 4) 
(16) 
( 4) 
( 4) 
(10) 
(40) 
( 3) 
( 6) 
( 4) 
(10) 
8 
7 
0 
0 
2 
13 
0 
8 
0 
16 
5 
3 
16 
3 
- 8 
- 7 
- 0 
- 0 
- 8 
- 12 
- 0 
- 14 
- 0 
- 5 
- 3 
- 0 
- 9 
- 3 
PR 
PR 
HR 
PD 
PD 
PR 
PD 
PD 
PD 
PR 
PR 
CR 
PR 
SD 
- PD (7)» 
- PD (7) 
(24* ) 
(3) 
(3) 
- ABMT (7) 
(3) 
(1,5) 
(5) 
(18*) 
(1,5) 
(14·) 
(3) 
(3) 
F: female, И: male,prex: prior treatment, VBCC: white blood c e l l count, BCM: below 
the costal margin, PTV: pretreatment value, LVR: lowest value reached, EOT: end of 
treatment, ABMT: al logeneic bone marrow transplantation. 
1: time from diagnosis unt i l treatment with rHuIFN-агс, 2: in brackets the time in 
weeks to LVR, 3: in brackets the time of treatment with гНиІГИ-агс in months. 
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(1 HR, 6 PR) received maintenance treatment 5 χ 10e units 
rIFN-a2c twice weekly. The patient with HR achieved CR after 
14 months of treatment, one other patient achieved HR after 
16 months of treatment. Three patients showed PD after 5, 7 
and 7 months of treatment respectively. One patient underwent 
allogeneic BMT after 7 months of treatment and is in CR. At 
the closing of the study 3 patients were still on maintenance 
treatment for 24 (HR), 18 (PR) and 14 (CR) months 
respectively. 
Leukocytes 
All patients showed a remarkable reduction of leukocytes with 
a minimal decrease of at least 45% (see Table 1). Time to 
achieve the lowest leukocyte count varied widely with a 
median of 10 weeks, ranging from 4 to 40 weeks. Six patients 
(43%) had an increase in leukocyte count, after initial 
regression, at the end of the 12 weeks induction period. 
Thrombocytes 
Mild thrombocytosis (>. 400 χ 109/1) was present in 4 patients 
varying from 427 up to 840 χ 10»/1. After institution of 
rIFN-azc in all patients a normalization was observed within 
4 weeks. One patient developed a thrombocytopenia during 
4 
treatment with гІРМ-осгс at a dose of 10 χ 10' units daily, 
which resolved after institution of maintenance treatment. 
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Spleen 
Ten patients (71%) had a palpable spleen. No change in spleen 
size during induction treatment was seen in 4 of these 
patients. In 2 patients an increase of spleen size was 
observed. Only 4 patients showed a decrease of the spleen 
size (40%). One of these had been treated for 5 months before 
the first reduction of spleen size was noticed. Four patients 
did not have a palpable spleen before or during treatment. 
Cytogenetics 
Only in the 2 patients with HR was cytogenetic analysis 
repeated according to the protocol. One of them showed a 50% 
reduction of the percentage of Ph'-chromosome positive 
metaphases after 5 months and a complete disappearance after 
14 months of treatment. 
Other investigations 
A reduction of the leukocyte count was accompanied by a 
decline of the LDH. The 2 patients with HR showed a decrease 
in Vit Bi ζ. No changes in LAP-scores were seen. 
Side effects 
Nearly all patients complained of influenza-like symptoms, 
starting about 4 - 6 hours after the first sc injections with 
fever, chills, headaches, myalgia. These symptoms disappeared 
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during the first week of treatment. Fatigue and loss of 
weight were common initial features. It appeared illusory to 
distinguish fatigue and weight loss as a disease activity 
from side effects of interferon. Five patients without 
symptoms at the onset of rlFN-orzc developed fatigue during 
the first few weeks of therapy. This was considered a side 
effect of rIFN-агс. One patient refused further therapy for 
this reason. No disturbances in renal or liver function were 
noticed. In one patient a dose dependent thrombocytopenia up 
to 50 χ 109/1 was seen during 10 χ IO6 units rIFN-a2c daily, 
resolving after institution of the maintenance dose ( 5 χ IO6 
units twice weekly.) 
DISCUSSION 
rIFN-az has been shown to be active in CML, with possible HR 
and even reduction of Ph'-chromosome, as has been reported by 
Talpaz and Niederle (see Table 2 ) e - 1 0 . The criteria of 
response are similar. During this study we have seen less 
favourable results. Especially the lack of reduction in 
spleen size was disappointing. No clear difference in patient 
selection was present. All patients suffered from Ph'-
chromosome positive CML, with or without prior treatment. We 
employed rIFN-агс which differs only 1 and 2 amino acids from 
rIFN-αζΒ and rIFN-OzA respectively. The biological activity 
of all recombinant interferon-α is similar in the treatment 
of HCL· 1 1 - 1 4. A possible explanation for the difference in 
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Table 2. Comparison between studies with interferon-α in CML. 
Talpaz1' Talpaz1' Niederle11 present study 
interferon HuIFN-α rHuIFN-ajA rHuIFN-агв rHuIFN-a2c 
dose: induction 3-9 χ 106U/m2 5 χ 10sU/m2 4 χ 10»U/m2 5-10 χ 106U 
daily daily daily daily 
maintenance 3 χ 10SU escalating till 1-10 χ 10eU 5 χ IO6 
every other response daily twice weekly 
day 
number of 
patients 
27 17 16 14 
pretreated with 
other drugs 
8 (30%) 14 (88%) 7 (50%) 
response 
(CR,HR,PR) 
24 (88%) 14 (82%) 14 (88%) 8 (57%) 
reduction in 
Ph'-chromosome 
7/27 (26%) 6/13 (46%) 4/12 (33%) 1/14 (7%) 
reduction in 
spleen size 
14/15 (93%) 5/5 (100%) 11/12 (92%) 4/10 (40%) 
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response may be the total dose of interferon used, although 
the induction doses seem comparable (see Table 2). The 
interferon dose during maintenance therapy was lower in 
comparison to the doses used by Talpaz and Niederle (see 
Table 2). One patient with PD while on maintenance therapy 
regained a PR with the institution of a higher dose (5 χ 10e 
units daily). 
Recombinant interferon-α has limited activity in the 
treatment of CML when used according to the protocol of this 
study. Several different approaches for future investigations 
are possible. Higher doses during the induction or 
maintenance period will be associated with an increase of 
side effects, presumably intolerable for a number of 
patients. Alternative subtypes of interferon like gamma-
interferon may show better anti-leukemic activity in CML, in 
view of its higher anti-proliferative properties13-16. 
Induction therapy with alkylating agents, such as busulfan, 
followed by maintenance therapy with interferon may be an 
attractive alternative. 
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CHAPTER 7 
Recombinant human interferon-gamma as a maintenance treatment 
in chronic myelogenous leukemia after cytoreduction 
by cytostatic drugs. 
M. Abegg-Werter, T. de Witte, В. de Pauw, R. Kurstjens, 
J.Burghouts, С. Haanen 
Submitted 
ABSTRACT 
Twelve patients with newly diagnosed Ph'-chromosome positive 
chronic myelogenous leukemia were treated with busulfan or 
hydrea to induce a clinical remission (leukocytes < 8 χ 
10e/1, spleen not palpable). Then maintenance therapy was 
instituted with recombinant interferon-tf (rlFN-tf) 0.5 mg 
thrice weekly. The dose and frequency of administration were 
adapted to maintain the leukocyte count between 3 and 8 χ 
10'/1. Two patients were unassessable for response, one due 
to severe side effects (grade IV weight loss), the other 
because of lack of compliance. Three out of 10 évaluable 
patients showed progressive disease after 9, 12 and 18 months 
of interferon treatment, respectivily. Two of them are still 
in a chronic phase controlled by busulfan, the third patient 
showed a lymphoblastic transformation while on interferon. 
One patient was treated with an allogeneic bone marrow 
transplantation after 8 months of maintenance treatment with 
rIFN-ri. In 6 patients rIFN-tf was continued during the 
observation period. Two of them obtained a cytogenetic 
conversion to 20% and 0% Ph'-chromosome positive metaphases 
after б and 18 months respectively. Flu-like symptoms, not 
alleviating during the course of treatment, were present in 
all patients, not completely controlled by paracetamol. rlFN-
tf appears of value as maintenance treatment in CML but 
additional investigations are warranted to assess the long 
term therapeutical value. 
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INTRODUCTION 
The median survival of patients with chronic myelogenous 
leukemia (CML) has not improved over the last 30 years, 
despite the availability of cytostatic agents such as 
busulfan and hydroxyurea1- * . Long-term eradication of the 
Ph'-chromosome and potential cure is only possible in a 
subgroup of patients when treated with allogeneic bone marrow 
transplantation. However, this procedure is limited to 
patients below 50 years of age with an HLA-identical donor5-
7
 . Interferon-α (rIFN-a) induces reduction or even 
disappearance of the Ph'-chromosome in a minority of patients 
with CMLe-9. However, the vast majority of patients 
experienced progressive disease after 6 to 12 weeks of 
treatment with rIFN-a during a previous study10. In vitro, 
interferon-^ (rIFN-tf) appeared to be a more powerful 
suppressor of myeloid precursor cells than rlFN-cc11 · 1 2 . A 
limited number of clinical studies on the effect of rIFN-τί in 
CML showed cytoreductive properties with possible minor 
reduction of the Ph'-chromosome, when given as a remission 
induction agent 1 3· 1 4. This paper describes the results of a 
phase II study on the value of rIFN-tf maintenance therapy in 
Ph'-chromosome positive CML patients after initial 
cytoreduction by cytostatic drugs. 
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MATERIAL AND METHODS 
Patient population 
All patients had recently diagnosed Ph'-chromosome positive 
CML without signs of acceleration or blastic transformation. 
Interferon 
Recombinant interferon-^ (rlFN-tf) was supplied in ampoules of 
0.5 mg lyophilizate, of >. 98% purity and a specific activity 
of 2 χ 107 U/mg by Boehringer Ingelheim BV, Alkmaar, The 
Netherlands. 
Treatment scheme 
Initial treatment consisted of an induction phase with 
busulfan or hydroxyurea until a clinical remission was 
obtained (leukocytes < 8 χ 10*/1, spleen not palpable). In 
case of a clinical remission, maintenance treatment was 
instituted consisting of 0.5 mg rlFN-d thrice weekly se as a 
starting dosage. Frequency and dose were adapted to obtain a 
leukocyte count between 3 χ 10s/1 and 8 χ 10'/1 (see Table 
1). The subcutaneous injections were administered by the 
patients themselves on an out-patient basis. 
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Table 1. Dosis adaptation scheme in case of leukopenia. 
leukocytes1 
rIFN-rf2 
leukocytes 
rIFN-tf 
rIFN-a 
3x 0.5 mg/week 
>8 
1 
>8 
X 
stop 
0.5 mg 
daily 
, 1 
з'з 
0. 5 mg 
daily 
3-8 I 2-3 
0.5 mg 
3x/week 
0. 5 mg 
2x/week 
r 
>8 
3-8 
i 
0. 5 mg 
3x/week 
0.5 mg 
2x/week 
<2 
I 
stop 
π 1 
2-3 <2 
i i 0.25 mg 
2x/week 
stop 
1. χ 10«/1 
2. recombinant interferon-gamma 
Evaluation 
Pretreatment evaluation included physical examination, 
determination of blood cell counts, liver and kidney function 
and measurement of Vit Bi г , LDH and alkaline phosphatase 
score of the leukocytes (LAP-score). Bone marrow aspiration 
was performed for conventional investigation and cytogenetic 
analysis. Before institution of maintenance treatment with 
rIFN-tf, the pretreatment evaluation was repeated except for 
cytogenetic analysis and additionally echography was 
performed to estimate the size of the spleen. Follow-up 
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evaluations of the blood counts were performed fortnightly 
for the first month of rlFN-tf treatment, followed by monthly 
evaluations thereafter. Echography of the spleen was repeated 
at 3 months intervals. Bone marrow morphology and 
cytogenetics were repeated at 6 months intervals. 
Definitions of response were: 
- Clinical remission (Clin R): leukocyte count of < 8 χ 10'/1 
and no palpable spleen. 
Complete remission (CR): complete disappearance of signs 
and symptoms with normalization of blood values, blood and 
bone marrow smears with complete disappearance of the Ph'-
chromosome. 
Hematological remission (HR): identical to complete 
remission but with persistance of the Ph'-chromosome. 
- Stable disease (SD): persistence of blood and bone marrow 
smears in concordance with CML. 
- Progressive disease (PD): deterioration of leukocyte count 
with appearance of immature cells and/or increment of spleen 
size and/or emergence of signs of acceleration or blastic 
transformation. 
RESULTS 
Sixteen patients were diagnosed to suffer from CML. Three of 
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Table 2. Clinical data. 
pat sex age B/H2 mg induction3 rlFN-tf maintenance 
F/K1 years period in dose period in 
months months 
1 F 71 В 658 15 
2 M 31 В 492 
3 M 63 В 436 
4 F 66 В 750 17 
5 F 46 В 274 3 
6 M 31 В 296 
7 M 37 В 520 
8 M 33 В 414 
9 F 49 В 302 
10 M 21 В 326 
11 F 59 В 392 
12 M 62 H 175 8 
0,5 mg 
3x weekly 
0,5 mg 
3x weekly 
0,5 mg 
daily 
0,5 mg 
3x weekly 
0,5 mg 
2x weekly 
0,25 mg 
2x weekly 
0,5 mg 
daily 
0,5 mg 
3x weekly 
0,5 mg 
2x weekly 
0,5 mg 
3x weekly 
0,5 mg 
3x weekly 
0,5 mg 
3x weekly 
12 
0,5 
24* 
18 
15' 
12* 
15* 
8 
result/comment 
grade IV 
weight loss 
PD4 
busulfan 12* months 
PD< 
busulfan 24* months 
lack of patients 
compliance 
CR4 
0% Ph'-chromosome 
PD« 
blastic 
transformation 
HR" 
20-36% Ph'-chrom 
bone marrow 
transplantation 
1) F=female, M=male 
2) cytoreduction in induction phase with B=busulfan or H=hydoxyurea 
3) duration of induction period in months 
4) PD=progressive disease, HR=hematological remission, CR=complete remission 
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them achieved no clinical remission. In one patient a 
persistent thrombocytosis was present. Two patients entered a 
blastic transformation. A fourth patient was treated with an 
allogeneic bone marrow transplantation before a clinical 
remission was present. Twelve patients (7 male, 5 female) 
were enrolled in the maintenance part of this open phase II 
study from February '86 until August '89. The clinical data 
are summarized in Table 2. Clinical remissions were obtained 
by busulfan (llx) or hydroxyurea (lx) in 3 to 17 months of 
treatment (median 5 months). Maintenance treatment with rlFN-
tf was given for 1* - 24* months. Two patients were 
inevaluable for response, one because of severe side effects 
(> 10% weight loss) after 2 months of rlFN-jf treatment, the 
other because of lack of compliance after 3 weeks of 
treatment. 
Hematological and cytogenetic response 
Of the 10 patients évaluable for response to rIFN-tf, 3 showed 
progressive disease after 9, 12 and 18 months of rIFN-tf 
treatment respectively. Two of them were retreated with 
busulfan, resulting in a chronic phase of 12* and 24* months 
respectively. One patient showed a lymphoblastic 
transformation while on rlFN-tf treatment for 18 months and 
was taken off study. One patient was treated with an 
allogeneic bone marrow transplantation after 8 months of 
successful maintenance treatment with rIFN-tf. Six patients 
106 
Table 3. Serial cytogenetic analysis in patients treated 
with recombinant interferon-gamma as a maintenance 
treatment. 
Percentage of Ph'-chromosome positive metaphases 
Months of treatment with rIFN-tf 
Pat. О» б 12 18 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
100 >>3 
100 
100 
100 >> 
100 
100 
100 
100 
100 
100 
100 
100 
1) At diagnosis CML 
2) — = no cytogenetic analysis due to protocol violation 
3) >> = off study 
100 >> 
2 >> 
24 4 0 
100 100 100 >> 
96 — 100 
100 100 
20 36 
100 
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were still on maintenance treatment with rIFN-a for 1*- 24* 
months (median 9* months). Three of them maintained a stable 
disease with 0.5 mg rIFN-tf thrice weekly. In one patient the 
administration of rlFN-tf had to be increased to daily to 
maintain a stable disease. In 2 patients a dose reduction to 
twice weekly 0.5 mg rIFN-tf was necessary because of a 
leukocytopenia (<3,0 χ 10'/1) with relative lymphocytosis. 
Both patients obtained a cytogenetic conversion with 20% and 
0% Ph'-chromosome positive metaphases after 6 and 18 months 
of rIFN-tf respectivily (see Table 3). 
Thrombocytes 
In 2 patients thrombocytosis > 400 χ IO9/1 emerging during 
rIFN-tf was the first sign of progressive disease. In one of 
them it was accompanied by venous thrombosis of the right 
vena saphena magna. 
Spleen 
In 2 out of 3 patients, disease progression while on rIFN-u 
maintenance treatment was associated with splenomegaly. Both 
patients are in chronic phase CML without splenomegaly for 
12* and 24* months since retreatment with busulfan. The third 
patient developed a lymphoblastic transformation without 
splenomegaly. 
108 
Vit Bi 2 and LAP-score 
In 3 patients a normalization of Vit B12 was noticed. Two of 
them had a normalization of the LAP-score and a reduction in 
Ph'-chromosome positive cells. 
Side effects of rIFN-d 
All patients complained of flu-like symptoms, such as fever, 
chills, myalgia and headaches, persisting up to 24 hours 
after injection, and none of them developed tolerance in 
time. Side effects were tolerable by using paracetamol, 
although they interfered daily life activities. In one 
patient a reversible WHO-grade IV side effect was noticed 
(>10 % weight loss in 2 months of treatment). This patient 
was taken off study. Four patients noticed mental 
disturbances such as bad temper, depressive feelings, apathy 
and loss of concentration. Occasionally arthralgia, 
diarrhoea, urticaria, the occurrence of acne and amenorrhoea 
were noticed. 
DISCUSSION 
This study analysed the clinical activity of rlFN-tf given as 
a maintenance treatment for patients suffering from CML in 
first chronic phase. In vitro investigations suggested a 
correlation between tumor load and efficacy of interferon1'. 
Cytoreduction with cytostatic drugs was performed to obtain a 
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minimal tumor load aiming at higher response rates with more 
cytogenetical conversions by rIFN-d. In this study we 
observed a substantial reduction of Ph'-chromosome positive 
metaphases in 2 cases, an observation which has not been 
reported so far 1 3· 1 , 1. Randomized studies are necessary to 
investigate a correlation between response and tumor burden 
in vivo. The activity of rIFN-tf in CML is possibly obtained 
by a direct cytostatic effect on myeloid precursor cells as 
interferon-a16-l9. The presence of monocytes seemed to be 
necessary to obtain the cytostatic effect of rIFN-τί, such in 
contrast to interferon-α20. Interferon-o is known to be an 
effective drug in CML with a higher percentage of cytogenetic 
conversions compared to interferon-^'·». In-vitro synergistic 
activity of interferon-α and -T¡ has been shown in Ph'-
chromosome positive CFU-GM21 · г 2 . It is tempting to speculate 
about a synergistic effect of interferon-α and -tf in 
attaining cytogenetic conversion in CML. 
The treatment with rlFN-tf was hampered by persisting side 
effects, alleviated by paracetamol but still interfering 
daily life activities. Until now no irreversible side effects 
of the interferons have been reported, in contrast to the 
side effects of alkylating drugs: induction of secondary 
malignancies, unpredictable prolonged hypoplasias and lung 
fibrosis 1· 3' 4· 2 3· 2 4. The persisting side effects of the 
interferons are still troublesome even if the interferons 
would delay a blastic transformation. In this regard an 
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increase of side effects in the combination of rIFN-a and -tf 
could interfere the clinical efficacy29. Autologous bone 
marrow transplantation in patients with cytogenetic 
conversion while on interferon treatment, may be an 
alternative approach. 
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SUMMARY 
Summary 
The interferons are a group of glycoproteins with antiviral, 
antiproliferative and immunomodulatory properties, which have 
been extensively investigated in vitro. Only during the last 
decade after DNA recombinant interferons became available in vivo 
studies have been performed. In Chapter 1 the present knowledge 
about the interferons is reviewed briefly with special attention 
to the results and side effects in the treatment of patients 
suffering from Hairy Cell Leukemia (HCL), Essential Thrombocytosis 
(ET) and Chronic Myelogenous Leukemia (CML). 
In Chapter 2 the results of a Dutch multi-center trial in 
patients suffering fom HCL treated with recombinant interfегоп-агс 
(rIFN-α) are reported. The first 8 patients have been treated in a 
Phase I dose-finding study with doses of rIFN-α up to 40 χ 10« U 
daily and 21 other patients according to an open phase II study 
with conventional doses of rIFN-α (5 χ 10е U daily). A remarkably 
high response rate of > 90% was registered, unfortunately at the 
cost of many side effects , which appeared to be dose-dependent 
and interfering daily-life activities. 
In an attempt to reduce side effects without diminishing the 
response rates in patients suffering from HCL, two additional 
studies have been performed. In Chapter 3 18 patients treated 
with rIFN-α (2 χ 10* U/m2 daily) were compared to 21 patients 
treated with optimal biological response-modifying doses of rlFN-
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α, using neopterin as a marker of macrophage activation. In each 
patient the minimum dose of rIFN-a inducing the maximum serum 
neopterin concentration was defined as the treatment dose (0.2-0.6 
χ 106 U/m2 daily). Both dose regimens were equally effective. 
Patients treated with the low-dose regimen remained almost 
completely free of side effects. 
In Chapter 4, the results of a second Dutch multicenter trial are 
presented. A comparison in response rate and side effects was made 
between patients treated with conventional dose гІРМ-агс (5x 10« U 
daily) and low-dose rlFN-ajA (1,5 χ 10s U thrice weekly). The 
overall response rate appeared to be unaffected by a reduction of 
the rIFN-a dose. A slight delay in recovery time of granulocytes 
and monocytes was observed, not resulting in an increase of 
infection rates. The number of side effects was not significantly 
reduced, but in the low-dose group the side effects did not 
interfere anymore daily life activities. 
In Chapter 5, the results of an open phase II study in 8 patients 
suffering from ET treated with either rIFN-o (6 patients) rIFN-tf 
(6 patients) are presented. Hematological remission, defined as a 
decrease in thrombocytes to <. 350 χ 109/1, was observed in none of 
the patients treated with rIFN-tf 0.5 mg thrice weekly. Five out of 
6 patients treated with rlFN-ot 5x 10e U daily achieved a 
hematological remission. A reduction of the dosing frequency to 5x 
and 3x weekly appeared to be feasible without a loss of efficacy. 
Side effects were persistent in patients treated with rlFN-tf and 
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present in the first month of treatment only in patients treated 
with rIFN-a, disappearing after dose reduction. rIFN-a may be an 
effective drug in treating ET. 
In Chapter 6, an open phase II multi-center study is reported of 
14 patients suffering from newly diagnosed Ph'-chromosome positive 
CML, who were treated initially with a high-dose rIFN-a (5 - 10 χ 
IO6 U daily), followed by a maintenance treatment of 5x IO6 U 
twice weekly. Only in 2 patients a sustained control of leukocyte 
counts and spleen size was seen. In one of them a complete 
cytogenetical conversion was observed. Most patients had 
progressive disease within three months of rIFN-a treatment. All 
patients showed an initial decline in their leukocyte counts of > 
45%. rIFN-o is an active compound in patients suffering of CML and 
occasionally a sustained response is achieved. 
In Chapter 7, a second open phase II study of 12 patients 
suffering from Ph'-chromosome positive CML, newly diagnosed, is 
described. After an initial treatment with busulfan or hydroxyurea 
leading to a clinical remission (normal spleen size and normal 
leukocyte counts) maintenance treatment was instituted: rlFN-tf 0.5 
mg thrice weekly. The dose and frequency of rIFN-tf administration 
was adapted individually in order to maintain the leukocyte counts 
between 3 and 8 χ 109/1. In 6 patients a sustained control of 
leukocyte counts was achieved, resulting in one complete 
cytogenetical conversion and one reduction to 20-35% Ph'-
chromosome positive metaphases. The side effects encountered in 
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this study were disappointing; they did not alleviate during the 
course of treatment and interfered the daily life activities. 
GENERAL CONCLUSION 
α-Interferon is treatment of choice in HCL especially the low-dose 
treatment. Further investigations are warranted to see whether 
continuous maintenance treatment or discontinuous treatment are 
more beneficial for the patient in view of survival and side 
effects. 
In ET activity of α-interferon is present. Confirmation of our 
results in larger studies are needed. 
In CML both a- and tf-interferon have shown activity, even with 
reduction or disappearance of the Ph'-chromosome. It is unclear 
whether any effect on the survival time is present. Large 
randomized studies are warranted on this issue. 
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SAMENVATTING 
Samenvatting 
Interferonen zijn een groep glycoproteinen met antivirale, 
antiproliferatieve en immunomodulatoire eigenschappen, die 
uitgebreid onderzocht zijn in vitro. Pas in de laatste 10 jaren 
zijn de interferonen in vivo toegepast met name na de introductie 
van de DNA recombinant interferonen. In Hoofdstuk 1 is in het 
kort de huidige kennis van de interferonen weergegeven. Speciale 
aandacht gaat daarin uit naar de resultaten en bijwerkingen van 
de interferonen in de behandeling van patiënten lijdende aan Hairy 
Cell Leukemie (HCL), Essentiële Thrombocytose (ET) en Chronische 
Myeloïde Leukemie (CML). 
In Hoofdstuk 2 zijn de resultaten weergegeven van een Nederlands 
multicenter onderzoek naar de behandelingsresultaten van 
recombinant interferon-azс (rIFN-α) bij patiënten die lijden aan 
HCL. De eerste 8 patiënten werden behandeld conform een fase I 
studie (een studie om de maximaal tolereerbare dosis vast te 
stellen) met doses rIFN-α tot 40 χ 10е U per dag. Een en twintig 
andere patiënten werden behandeld conform een fase II studie met 
conventionele doses rIFN-α (5x 10е U per dag). Opvallend was het 
hoge respons percentage van meer dan 90%, helaas ten koste van 
zóveel bijwerkingen dat de patiënten gehinderd werden in het 
uitvoeren van hun dagelijkse activiteiten. 
In een poging de bijwerkingen te verminderen met behoud van 
effectiviteit zijn twee vervolg-studies bij patiënten lijdende 
aan HCL uitgevoerd. In Hoofdstuk 3 zijn twee patiënten-groepen 
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met elkaar vergeleken. Achttien patiënten werden behandeld met de 
conventionele dosis rlFN-ot (2 χ IO6 units/m2 dagelijks 
toegediend), 21 patiënten werden behandeld met die dosis rIFN-a 
die de hoogste biologische activiteit. De biologische activiteit 
werd afgemeten aan de neopterine concentratie in het serum. In 
deze groep varieerden de dagelijkse doses van 0.2 tot 0.6 χ 
IO6units/m2. Beide regiems bleken even effectief. Bij de 
patiënten behandeld met de lagere doses werden echter nauwelijks 
bijwerkingen geconstateerd. 
In Hoofdstuk 4 zijn de resultaten van een tweede Nederlandse 
multicenter studie weergegeven. De mate van effectiviteit en 
bijwerkingen zijn vergeleken tussen twee groepen patiënten 
lijdende aan HCL. De eerste groep werd behandeld met een 
conventionele dosis rIFN-a (dagelijks 5 χ 10* U), de tweede groep 
met een lagere dosis rIFN-oc (1,5 χ IO6 U 3x per week). Het 
verminderen van de dosis bleek niet van invloed op het response­
percentage. De bijwerkingen waren niet significant afgenomen in 
aantal maar leken minder te interfereren met de dagelijkse 
activiteiten van de patiënten. 
In Hoofdstuk 5 zijn de resultaten weergegeven van een fase II 
studie. Acht patiënten lijdende aan ET werden behandeld met rIFN-a 
(6 patiënten) of rlFN-tf (6 patiënten). Een hematologische 
remissie, gedefinieerd als een afname van het aantal thrombocyten 
tot <. 350 χ 109/1, werd geen enkele maal gezien in de groep 
patiënten behandeld met rIFN-?i. Vijf van de zes patiënten 
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behandeld met rIFN-α bereikten wel een hematologische remissie. 
Een reductie in toedienings frekwentie tot 5x en 3x per week bleek 
mogelijk met behoud van respons. De bijwerkingen bij patiënten 
behandeld met rIFN-tf bleven continu aanwezig, zonder enige 
adaptatie in tijd. Patiënten die behandeld werden met rIFN-a, 
hadden allen in de eerste maand bijwerkingen die verminderden en 
verdwenen na dosisreductie. rIFN-α blijkt effectief in de 
behandeling van ET. 
In Hoofdstuk 6 zijn de resultaten weergegeven van een fase II 
multicenter studie. Veertien patiënten lijdende aan CML zijn 
initieel behandeld met hoge doses rIFN-a variërend van 5 tot 10 χ 
IO6 units dagelijks. De onderhoudsbehandeling bestond uit 5 χ 10e 
units rIFN-α, 2x per week toegediend. Slechts bij 2 patiënten werd 
gezien dat het aantal leukocyten en de miltgrootte blijvend 
normaliseerden. Bij één van hen werd tevens vastgesteld dat het 
Ph'-chromosoom niet meer aantoonbaar was. De meeste patiënten 
vertoonden een progressie van het ziektebeeld binnen 3 maanden na 
het starten van de rIFN-α therapie. Alle patiënten vertoonden 
aanvankelijk een daling van het aantal leukocyten tot minder dan 
55% van de uitgangswaarde. rIFN-α is werkzaam in de behandeling 
van patiënten lijdende aan CML, soms resulterend in een blijvende 
respons en cytogenetische conversie. 
In Hoofdstuk 7 is een andere fase II studie betreffende CML-
patiênten weergegeven. Na een cytoreductie met behulp van busulfan 
of hydroxy-ureum, resulterend in een klinische remissie (normale 
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miltgrootte en normaal aantal leukocyten), werd een 
onderhoudsbehandeling gegeven met rIFN-tf. De initiële dosis 
bedroeg 0.5 mg rlFN-tf 3x per week. Om het aantal leukocyten tussen 
de 3 en 8 χ 109/1 te houden werd de dosis aangepast. Bij 6 
patiënten bleek het mogelijk het aantal leukocyten blijvend te 
controleren met behulp van rIFN-tf. Dit resulteerde bij 1 patiënt 
in een complete cytogenetische conversie; bij een andere patiënt 
werd een daling in het aantal Ph'-chromosoom positieve metafasen 
tot 20-36% gezien. Teleurstellend waren het bijwerkingen, die 
gedurende de gehele behandeling persisteerden en die het 
dagelijkse funktioneren van de patiënt nadelig beïnvloedden. 
ALGEHELE CONCLUSIE 
Zelfs in lage dosering is α-interferon de beste behandeling voor 
HCL-patiënten. Verder onderzoek naar overleving en subjectieve 
beleving is nodig om vast stellen of een continue 
onderhoudsbehandeling te prefereren valt boven een behandeling met 
therapievrije periodes. 
In ET is α-interferon werkzaam. Grotere studies zijn nodig om onze 
gegevens te bevestigen. 
Zowel α- als ^-interferon zijn werkzaam in de behandeling van 
patiënten lijdende aan CML. Een afname en zelfs verdwijnen van het 
Ph'-chromosoom werd gezien. Vraag blijft of het verminderen van 
het Ph'-chromosoom van invloed zal zijn op de overlevingsduur. 
Gerandomizeerde studies zijn nodig om dit te onderzoeken. 
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STELLINGEN 
1. Interferon-α is momenteel eerste keus als medicamenteuze 
behandeling van hairy cell leukemie . 
2. Bij de behandeling van hairy cell leukemie blijkt 
verlaging van de dosis interferon-α zeer wel mogelijk 
met behoud van effectiviteit en afname van bijwerkingen. 
3. Door behandeling van chronische myeloïde leukemie met 
interferon kan de chromosomale afwijking (PH'-
chromosoom) tijdelijk niet aantoonbaar zijn. 
4. Sinds de introductie van interferon is het mogelijk 
enkele chronische bloedziekten te behandelen zonder 
blootstelling aan cytostatica. 
5. Op dit moment is het nog onduidelijk of behandeling met 
interferon levensverlengend is bij patiënten lijdende 
aan chronische myeloïde leukemie of essentiële 
thrombocytose. 
6. Door behandeling met interferon-α is het voor patiënten 
lijdende aan een hairy cell leukemie mogelijk wederom 
als volwaardig lid van gezin en maatschappij te 
functioneren. 
7. De bijwerkingen van interferon-α zijn dosisafhankelijk 
en nemen af in de tijd, in tegenstelling tot de 
bijwerkingen van interieron-τί die persisteren en 
hierdoor subjectief slechter te tolereren zijn. 
8. Indien lokale behandeling wordt overwogen bij de ziekte 
van Hodgkin is stadiëringslaparotomie niet obsoleet, 
ondanks de moderne beeldvormende technieken. 
9. Als salaris een maat is voor de te verwachten prestatie, 
mag van AIO's slechts een minimum aan onderzoeks-
resultaat verwacht worden. 
10. Voor het verkrijgen van een betrouwbare "A" is om 
esthetische redenen het aanslaan van de stemvork aan de 
schedel te prefereren boven de hak. 
11. Een wetenschappelijke promotie en sociale promotie zijn 
strijdig met elkaar. 
12. Het fuseren van twee ziekenhuizen vertoont opvallende 
overeenkomst met echtscheidingsproblematiek. 
13. Van veel publiceren wordt men geen betere dokter. 



